Dual targeting for specific delivery of central nervous system cells
By developing MGS peptides and MTS peptides and their compositions, using their targeted properties, the problem of drug delivery to the central nervous system is solved, efficient and safe drug delivery is achieved, and biodistribution in the prior art is avoided. and structural damage problems.
Patent Information
- Application Number
- CN202280092194.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-09-30
- Filing Date
- 2022-12-20
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art is difficult to effectively deliver drugs to the central nervous system, especially due to the existence of the blood-brain barrier, which makes most drugs unable to pass through, and existing methods have problems such as uneven biodistribution, toxicity and structural damage.
MGS peptides and MTS peptides and their compositions have been developed to achieve drug use the targeted nature of these peptides to enter the central nervous system by coupling with carriers, and to selectively bind specific cell types such as microglia. Targeted delivery.
It realizes efficient and selective delivery of drugs to the central nervous system, improves the biodistribution characteristics and safety of drugs, and reduces the risk of damage to surrounding tissues.
Smart Images

Figure CN119031940A_ABST
Abstract
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 292,370, filed on December 21, 2021, and U.S. Provisional Application No. 63 / 412,220, filed on September 30, 2022; each of which is incorporated herein by reference in its entirety. About Sequence Listing
[0002] The sequence listing entitled "37794_0099P1.xml", filed as ST.26 file on December 20, 2022, created on December 20, 2022, and 18251 bytes in size, is incorporated herein by reference pursuant to 37 CFR §1.52(e)(5. Background of the Invention
[0003] Access to the central nervous system (CNS) is a bottleneck in the development of neurotherapeutic drugs. This is due to the presence of the blood-brain barrier (BBB). The blood-brain barrier is a set of specialized and highly selective cell barriers that protect the central nervous system (CNS). Although the blood-brain barrier is necessary under normal physiological conditions, it prevents many chemicals (such as neurotherapeutic drugs) from entering the brain. Therefore, less than 5% of small molecule drugs are able to cross the blood-brain barrier. In addition, due to the existence of the blood-brain barrier, newer biological therapies such as antibodies and gene therapies are essentially unable to enter the central nervous system. Although the discovery of the blood-brain barrier has a history of more than 100 years, a universal solution for delivering drugs to the central nervous system has not yet been established. Therefore, many central nervous system disorders have no treatment options.
[0004] Several approaches have been used by others to deliver drugs to the central nervous system. One approach is to use compounds that can cross the blood-brain barrier. The problem with using compounds that can cross the blood-brain barrier is that they often have poor biodistribution properties and off-target effects (because they are usually highly lipid-soluble). Since less than 5% of small molecules can cross the blood-brain barrier, there are very few compounds that can penetrate the blood-brain barrier. Drugs that can cross the blood-brain barrier have very limited indications.
[0005] Another way to access the central nervous system is through direct injection into the spinal cord or brain. This approach is invasive and carries the risk of structural damage to surrounding tissues, as well as an increased risk of infection.
[0006] Disruption of the blood-brain barrier is another approach used. This approach allows for massive transport of compounds, cells, and pathogens into the central nervous system. This approach may result in structural damage as well as neurological dysfunction.
[0007] Intranasal delivery has also been used. This approach is only suitable for small molecule drugs that are lipid soluble. Intranasal delivery has been shown to have poor distribution in the central nervous system. In addition, there is variability in the absorption of intranasal delivery at different doses and between patients.
[0008] Receptor-mediated delivery (Trojan Horse) methods are also used. This method lacks universality because it is usually only effective for a single cargo. These receptors can be expressed in multiple tissues, resulting in poor uptake and toxicity in the central nervous system. In addition, most receptor-mediated delivery lacks cell specificity after crossing the blood-brain barrier and has inconsistent distribution in the central nervous system.
[0009] There are currently no known choroid plexus transporters or other methods that can transport cargo across the blood-cerebrospinal fluid barrier, which provides a unique opportunity to develop new methods to affect the entry of drugs and macromolecules into the central nervous system. Therefore, compositions and methods for targeting the central nervous system are disclosed herein. Summary of the invention
[0010] Disclosed is an MGS peptide comprising an amino acid sequence of any sequence listed in SEQ ID NO: 1-8 as shown in Table 1.
[0011] Disclosed herein are MTS peptides. Disclosed are MTS peptides comprising an amino acid sequence of any of the sequences listed in SEQ ID NOs: 9-14 as shown in Table 2.
[0012] In some aspects, the linker comprises the following structure: Wherein, X is a peptide and R is a reactive group capable of chemically reacting with a moiety. In some aspects, X can be an MGS peptide or an MTS peptide. In some aspects, this structure can be referred to as a dimer core because it can connect two peptides.
[0013] In some aspects, the linker comprises the following structure: or Wherein, X is a peptide and R is a reactive group capable of chemically reacting with a moiety. In some aspects, X can be an MGS peptide or an MTS peptide. In some aspects, this structure can be referred to as a tetramer core because it can connect four peptides. Another example of a tetramer core includes the following structure: Wherein, X is a peptide and R is a reactive group capable of chemically reacting with a moiety. In some aspects, X can be an MGS peptide or an MTS peptide. Disclosed are compositions comprising at least one MGS peptide coupled to at least one MTS peptide, wherein the MGS peptide comprises the amino acid sequence GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1); EQRWVQMLHLQTRYAGEWPG (SEQ ID NO: 2); FQHNPFPYTYSMEDTVEIK (SEQ ID NO: 3); or YAAWPASGAWT (SEQ ID NO: 4).
[0014] Disclosed are compositions comprising two or more MGS peptides coupled to two or more MTS peptides, wherein the two or more MGS peptides comprise the amino acid sequence GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1); EQRWVQMLHLQTRYAGEWPG (SEQ ID NO: 2); FQHNPFPYTYSMEDTVEIK (SEQ ID NO: 3); or YAAWPASGAWT (SEQ ID NO: 4).
[0015] Disclosed is a composition comprising four MGS peptides coupled to two MTS peptides, wherein the four MGS peptides respectively comprise the amino acid sequences GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1); EQRWVQMLHLQTRYAGEWPG (SEQID NO: 2); FQHNPFPYTYSMEDTDVEIK (SEQ ID NO: 3); or YAAWPASGAWT (SEQ ID NO: 4); wherein the two MTS peptides respectively comprise the amino acid sequences DAYKLQTSLDWQMWNP (SEQ ID NO: 9); FPSWTSKNQQWTNQRQ (SEQ ID NO: 11); or SKETYSMNAQRQHERS (SEQ ID NO: 13).
[0016] Disclosed is a composition comprising the following components: an MGS peptide comprising the amino acid sequence GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1); EQRWVQMLHLQTRYAGEWPG (SEQ ID NO: 2); or FQHNPFPYTYSMEDTDVEIK (SEQ ID NO: 3); a first linker comprising (i) at least one reactive group capable of binding to the C-terminus of the peptide; and (ii) at least one other reactive group capable of chemically reacting with a portion; a second linker; a third linker comprising (i) at least one reactive group capable of binding to the C-terminus of the peptide; and (ii) at least one other reactive group capable of chemically reacting with a portion; and an MTS peptide comprising the amino acid sequence DAYKLQTSLDWQMWNP (SEQID NO: 9); FPSWTSKNQQWTNQRQ (SEQ ID NO: 11); or SKETYSMNAQRQHERS (SEQ ID NO: 13).
[0017] Disclosed are methods of transporting a cargo to the central nervous system of a subject, comprising administering one or more compositions disclosed herein to a subject in need thereof, wherein a peptide coupled to the cargo enters the central nervous system.
[0018] Disclosed are methods of treating a central nervous system disorder or injury in a subject, comprising administering to a subject in need thereof one or more compositions disclosed herein, wherein the cargo is a central nervous system disorder or injury therapeutic agent.
[0019] Disclosed are methods of imaging the central nervous system of a subject comprising administering to the subject in need thereof one or more compositions disclosed herein, wherein the cargo is an imaging agent.
[0020] Other advantages of the disclosed methods and compositions will be set forth in part in the description below, in part will be understood from the description, or may be obtained by practicing the disclosed methods and compositions. The advantages of the disclosed methods and compositions will be realized and obtained by the elements and combinations particularly pointed out in the appended claims. It should be understood that the foregoing general description and the following detailed description are exemplary and explanatory only and do not limit the invention claimed for patent protection. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] The accompanying drawings, which are incorporated in and constitute a part of the specification, illustrate several embodiments of the disclosed methods and compositions and, together with the description, serve to explain the principles of the disclosed methods and compositions.
[0022] Figure 1 An example structure of CH3CO-YAAWPASGAWT (SEQ ID NO: 8), MGS2_V4 is shown.
[0023] Figure 2 An example structure of CH3-CO-GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO:5), MGS_NOE3_V2 is shown.
[0024] Figure 3A and 3B Dimer core (A) linker and tetramer core (B) linker are shown. X = any peptide, in particular MGS or MTS. R = attachment point for cargo (e.g. dye, imaging agent, therapeutic agent, protein, nucleic acid, carbohydrate, other peptide, lipid or other chemical modification).
[0025] Figure 4 A-4C shows an example structure of an MTS peptide. Figure 4 A shows an example of the MTS peptide Ac-DAYKLQTSLDWQMWNP, which is also referred to as MTS1_V2. Figure 4 B shows an example of the MTS peptide Ac-FPSWTSKNQQWTNQRQ, also known as MTS2_V1. Figure 4 C shows an example of the MTS peptide Ac-SKETYSMNAQRQHERS, also known as MTS3_V1.
[0026] Figure 5 An example structure of a dimer core with fatty acid modification is shown. The resulting MTS peptide is called MTS3_V2-2. This modification can also be used for MTS1 and MTS2.
[0027] Figure 6 Shown is a schematic of the experimental workflow used to study in vivo trafficking of MTs to the CNS.
[0028] Fig. 7A and 7B Lipidation of MTS3 with C16 fatty acids enhances transport into the cerebrospinal fluid (CSF) (A) and brain (B). MTS3_V1-2 is a dimer Ac-SKETYSMNAQRQHERS (SEQ ID NO: 14). MTS3_V2-2 is a C16 fatty acid modified dimer core with Ac-SKETYSMNAQRQHERS (SEQ ID NO: 14), comprising. scMTS3_V2-2 is a C16 fatty acid modified dimer core with a scrambled MTS3 sequence (scMTS3: RKSAYNQHSSQMREET: SEQ ID NO: 15).
[0029] Figure 8Shown is the enhanced brain accumulation of MTS3_V2-2 compared to the parental MTS3_V1-2 observed by brain sectioning and fluorescence imaging. Both forms were conjugated to the same near-infrared dye and the circulation time is summarized in each figure. The intensity scale bar is shown and is consistent in all images to facilitate comparison.
[0030] Figures 9A-9C It was shown that MGS2_V4-2 was specific for microglia cells and promoted high levels of cellular uptake. Fig.9A Shown are HMC3 cells (human microglial cell line) incubated with different concentrations of MGS2_V4-2 for 1 hour at 37° C. The EC50 (half maximal uptake) was 7.3 nM. Fig. 9B Shown is the uptake of MGS2_V4-2 measured at 1 hour in HMC3 cells exhibiting either a resting or activated phenotype. In both cell states, an average of approximately 60,000 molecules of MGS2_V4-2 were internalized. This suggests that MGS2_V4-2 is effective for delivery to microglia in both phenotypic states. Fig. 9C It was shown that the uptake in HMC3 cells was significantly higher than that in other cells of the central nervous system, indicating that MGS2_V4-2 is specific for microglia. All cell lines were incubated with 25 nM of MGS2_V4-2 for 1 hour at 37°C.
[0031] Fig.10 The results showed that the optimized MGS2_V4-2 was stable in human serum.
[0032] Fig.11 The structure of the MTS3_V1-2-MGS2_V4-2 chimera is shown. MGS2_V4. X' = MTS3_V1. R = attachment point for dye, imaging agent, therapeutic agent, protein, nucleic acid, other peptide, carbohydrate and / or lipid.
[0033] Fig.12 An example of internalization of a dual-targeted MTS-MGS chimera (MTS3_V1-2-MGS2_V4-2) into microglia is shown.
[0034] Figures 13A-13C An example of internalization of a dual targeted MTS-MGS chimera (MTS3_V1-2-MGS2_V4-2) into microglia as observed by confocal microscopy is shown. A single Z-slice is shown. Scale bar = 10 μm.
[0035] Figures 14A-14CThe dual targeting effect of the MTS3_V1-2-MGS2_V4-2 chimera targeting microglia in the central nervous system is shown. The MTS3_V1-2-MGS2_V4-2 conjugate is labeled with Alexa Fluor 647 (red) and injected into the lateral tail vein of Sprague Dawley rats at a dose of 0.09nmol / g. After 2 hours of circulation time, the animals were killed, and the brains were fixed, collected, cryoprotected by transcardial perfusion and cryosectioned into 15μm slices on a Leica CM1950. Images were taken using a Zeiss LSM 800. Microglia were stained with Iba-1 (grey) and nuclei were stained with Hoechst33342 (blue). Fig.14A and 14B Depicted are single Z-slice images of internalization of the MTS3_V1-2-MGS2_V4-2 conjugate into microglia, as confirmed by perinuclear staining but not adjacent non-microglial cells. Fig. 14C 3D rendering depicting internalization of the MTS3_V1-2-MGS2_V4-2 conjugate into microglia but not surrounding non-microglia (all images at 630x magnification).
[0036] Fig.15 The dual targeting effect of the MTS3_V1-2-MGS2_V4-2 chimera to target microglia in the central nervous system was shown, which was confirmed by flow cytometry.
[0037] Fig.16 The structure of the MTS3_V1-2-MGS2_V4-4 chimera is shown. MGS2_V4. X' = MTS3_V1. R = attachment point for dye, imaging agent, therapeutic agent, protein, nucleic acid, other peptide and / or lipid.
[0038] Fig.17 Shows the Fig.16 Compared to the structure of the MTS3_V1-2-MGS2_V4-4 chimera using another linkage. X = MGS2_V4. X' = MTS3_V1 or MTS2_V1 or MTS1_V2. R = attachment point for dye, imaging agent, therapeutic agent, protein, nucleic acid, other peptide, carbohydrate and / or lipid.
[0039] Fig.18A and 18B An example of using the MGS2-MTS3 chimera to deliver siRNA in microglia is provided. Fig.18AThe chimera MGS2_V4-4(tetramer)-MTS3_V1-2 is shown coupled to the test siRNA via click chemistry. Fig.18B The uptake of MGS2_V4-4-MTS3_V1-2 and MGS2_V4-4-MTS3_V1-2-siRNA is shown.
[0040] Fig.19 The structure of the tetrameric MGS_NOE3_V2-4 core is shown. X = MGS_NOE3_V2 peptide sequence CH3CO-GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 5). R = attachment point for materials, imaging agents, therapeutic agents, proteins, nucleic acids, carbohydrates, lipids and other peptides.
[0041] Fig. 20 The structure of the MGS_NOE3_V2 peptide sequence is shown. The sequence is CH3-CO-GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 5).
[0042] Figures 21A-21C It was shown that the tetrameric MGS_NOE3_V2-4 was specific for neural cells and promoted high levels of cellular uptake. Fig.21A It was shown that MGS_NOE3_V2-4 binds to two neuronal cell lines, but not to microglial or astrocyte cell lines. Fig.21B It was shown that the uptake of MGS_NOE3_V2-4 was concentration-dependent and internalized at high levels. Fig. 21C It was shown that uptake of MGS_NOE3_V2-4 lasted for at least 24 hours and reached an intracellular concentration of approximately 1 μM.
[0043] Fig. 22 Cellular receptor recycling of NOE_NOE3_V2-4 is shown. Chloroquine: inhibits receptor recycling; Cycloheximide: inhibits new protein synthesis.
[0044] Figures 23A-23C Internalization of MGS_NOE3_V2-4 into neuronal cells is shown. Scale bar represents 10 μm.
[0045] Figures 24A-24C Shown is the association of MGS_NOE3_V2-4 with cells in the central nervous system after intrathecal injection. (A) Sorting strategy for total brain cells versus debris. (B) Sorting strategy to exclude cell doublets. Fig.24C Represents the fluorescence intensity of MGS_NOE3_V2-4 internalized into brain cells after intrathecal injection compared with untreated animals.
[0046] Fig.25The structure of the MTS3_V1-2-MGS_NOE3_V2-4 chimera is shown. X = MGS_NOE3_V2. X' = MTS3_V1. R = attachment point for dyes, imaging agents, therapeutic agents, proteins, nucleic acids, other peptides and / or lipids.
[0047] Figures 26A-26C Internalization of the MTS3_V1-2-MGS_NOE3_V2-4 chimera into HT22 neuronal cells is shown. Fig.26A : MTS3_V1-2-MGS_NOE3_V2-4 chimera, MGS_NOE3_V2-4 or MTS3_V1-2 were incubated with HT22 cells at 200 nM for 1 hour. Peptide uptake data were obtained by quantitative flow cytometry assay. Fig.26B : Evaluation of MTS3_V1-2-MGS_NOE3_V2-4 chimera uptake in HT22 cells over time. Cells were incubated at 200 nM and the average uptake per cell was determined. Fig.26C : HT22 cells were incubated with Alexa Fluor 647-labeled MTS3_V1-2-MGS_NOE3_V2-4 chimera at 200 nM for the indicated times at 37°C. Alexa Fluor 488-conjugated wheat germ agglutinin was used to label the cell membrane, and Hoechst 33342 was used to stain the nucleus. Live cell imaging was performed, and representative images are shown.
[0048] Fig. 27 It was shown that MTS2_V1-2 binds to the transferrin receptor to enter the central nervous system, while MTS3_V1-2 utilizes a novel, yet unidentified, cellular receptor for transport.
[0049] Figures 28A-28E Examples of core architectures with PEG linkers are shown. a) Monomeric core with PEG linker. b) Dimeric core with PEG linker. c) Dimeric core with maleimide. d) Tetrameric core with PEG linker. e) Tetrameric core with maleimide. R = attachment point for dye, imaging agent, therapeutic agent, protein, nucleic acid, other peptide, carbohydrate and / or lipid. X = any MGS, MTS, MGS or MTS with attached core and / or linker.
[0050] Fig.29 Examples of coupling between a maleimide core (dimer (shown) or tetramer) and 2.2 equivalents of peptide (any core architecture (dimer shown)) are shown. X = MGS or MTS. R = attachment point for dyes, imaging agents, therapeutic agents, proteins, nucleic acids, carbohydrates, other peptides and / or lipids.
[0051] Fig.30Schematic diagram showing the addition of 1.2 equivalents of maleimide-PEG4-DBCO to 1 equivalent of peptide, any core structure (dimer shown). X = MGS or MTS.
[0052] Fig.31 An example of chimeric peptide synthesis between 1 equivalent of a peptide with an attached DBCO (any core architecture (dimer shown)) and 1.2 equivalents of a peptide with a modified lysine in the core (any core architecture (dimer shown)) is shown. X = MGS or MTS. R = attachment point for dyes, imaging agents, therapeutic agents, proteins, nucleic acids, carbohydrates, other peptides and / or lipids.
[0053] Fig.32 An example of coupling between 1.2 equivalents of a chimeric peptide (composed of any core architecture (tetramer / dimer chimeras are shown) with free DBCO and 1 equivalent of siRNA with free azide is shown. X = MGS or MTS. R = attachment point for dyes, imaging agents, therapeutic agents, proteins, nucleic acids, other peptides, carbohydrates and / or lipids. DETAILED DESCRIPTION
[0054] The disclosed methods and compositions may be understood more readily by reference to the following detailed description of specific embodiments, the Examples included herein, and the Figures and their preceding and following descriptions.
[0055] It should be understood that the disclosed methods and compositions are not limited to specific synthetic methods, specific analytical techniques or specific reagents, unless otherwise specified, and therefore may vary. It should also be understood that the terminology used herein is intended only to describe specific embodiments and is not intended to be limiting.
[0056] The disclosed materials, compositions, and components can be used in, used in conjunction with, used to prepare, or are products of the disclosed methods and compositions. These and other materials are disclosed herein, with the understanding that when combinations, subsets, interactions, groups, etc. of these materials are disclosed without explicitly specifically disclosing each of the various individual and collective combinations and permutations of these compounds, each of these is specifically contemplated and described herein. Thus, if a class of molecules A, B, and C is disclosed and an example of a class of molecules D, E, and F and a combination of molecules AD is disclosed, each of these combinations is contemplated individually and collectively even if each combination is not stated individually. Thus, in this example, each of the following combinations AE, AF, BD, BE, BF, CD, CE, and CF is specifically contemplated and should be considered disclosed by the contents of A, B, and C; D, E, and F; and the example combination AD. Likewise, any subset of the above or combination of these subsets is also specifically contemplated and disclosed. Thus, for example, the subgroups of AE, BF, and CE are specifically contemplated and should be considered disclosed from the disclosure of A, B, and C; D, E, and F; and the exemplary combination AD. This concept applies to all aspects of this application, including, but not limited to, steps in methods of making and using the disclosed compositions. Thus, if there are a variety of additional steps that can be performed, it should be understood that each of these additional steps can be performed by any specific embodiment or combination of embodiments of the disclosed methods, and each such combination is specifically contemplated and should be considered disclosed.
[0057] The titles are provided for convenience only and should not be construed as limiting the invention in any manner. The embodiments shown under any title or any section of the present disclosure may be combined with the embodiments described under the same or any other title or other section of the present disclosure. A. Definition
[0058] It should be understood that the disclosed methods and compositions are not limited to the specific methods, protocols and reagents described, as these may vary. It should also be understood that the purpose of the terminology used herein is only to describe specific embodiments and should not be intended to limit the scope of the present invention, which is limited only by the appended claims.
[0059] It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to an "MGS peptide" includes a plurality of such MGS peptides, reference to a "linker" refers to one / one or more / multiple linkers and equivalents thereof known to those skilled in the art, and so forth.
[0060] As used herein, "treatment / processing" means administering the compositions of the present invention to an object suffering from a disease or condition, such as a human or other mammal (e.g., an animal model), so as to prevent or delay the deterioration of the effects of the disease or condition or partially or completely reverse the effects of the disease or condition. In some aspects, the disease or condition may be a central nervous system (CNS) related disease or condition or a central nervous system disorder or injury. Treatment / processing may be given to an object that does not show signs of a disease, disorder, disorder, and / or condition and / or an object that only shows early signs of a disease, disorder, disorder, and / or condition, to reduce / reduce the risk of developing a pathology associated with a disease, disorder, or condition. In some embodiments, treatment / processing includes delivering one or more disclosed compositions to an object.
[0061] As used herein, "preventing" or "preventing" means minimizing the likelihood of a subject susceptible to developing a disease, disorder, condition or condition developing the disease, disorder, condition or condition.
[0062] As used herein, the term "subject" refers to the target of administration, such as a human. Therefore, the subject of the disclosed method can be a vertebrate, such as a mammal, fish, bird, reptile or amphibian. The term "subject" includes domesticated animals (e.g., cats, dogs, etc.), livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g., mice, rabbits, rats, guinea pigs, fruit flies, etc.). In one aspect, the subject is a mammal. In another aspect, the subject is a human. The term does not represent a specific age or gender. Therefore, the term is intended to cover male or female adults, children, adolescents, and newborn subjects and fetuses.
[0063] As used herein, the term "patient" refers to a subject suffering from a disease, disorder or disorder. The term "patient" includes both human and veterinary subjects. In some aspects of the disclosed methods, prior to the step of administering, the "patient" has been diagnosed as needing treatment. In some aspects, patient and subject can be used interchangeably.
[0064] As used herein, the term "amino acid sequence" refers to a list of abbreviations, letters, characters or words representing amino acid residues. The amino acid abbreviations used herein are the conventional single-letter codes for amino acids, which are represented as follows: A, alanine; C, cysteine; D, aspartic acid; E, glutamic acid; F, phenylalanine; G, glycine; H histidine; I isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; P, proline; Q, glutamine; R, arginine; S, serine; T, threonine; V, valine; W, tryptophan; Y, tyrosine.
[0065] As used herein, "polypeptide" refers to any peptide, oligopeptide, polypeptide, gene product, expression product or protein. A polypeptide is composed of consecutive amino acids. The term "polypeptide" encompasses naturally occurring or synthetic molecules.
[0066] In addition, as used herein, the term "polypeptide" refers to amino acids connected to each other by peptide bonds or modified peptide bonds, such as peptide isosteres, etc., and may include modified amino acids other than 20 gene-encoded amino acids. Polypeptides can be modified by natural processes (such as post-translational processing) or chemical modification techniques well known in the art. Modifications can occur anywhere in the peptide, including the peptide backbone, amino acid side chains, and amino or carboxyl termini. The same type of modification can exist in the same or different degrees at multiple sites of a given polypeptide. In addition, a given polypeptide can have many types of modifications. Modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent cross-linking or cyclization of flavin, covalent attachment, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of a phosphatidylinositol, disulfide bond formation, demethylation, formation of cysteine or pyroglutamate salts or esters, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, ulfation, transfer RNA-mediated addition of amino acids to protein, such as arginylation. (See Proteins-Structure and Molecular Properties, 2nd ed., E.C. Creighton, W.H. Freeman and Company, New York (1993); Posttranslational Covalent Modification of Proteins, BC Johnson, ed., Academic Press, New York, pp. 1-12 (1983).
[0067] As used herein, the phrase "nucleic acid sequence" refers to a naturally occurring or synthetic oligonucleotide or polynucleotide, whether DNA, RNA or DNA-RNA hybrid, single-stranded or double-stranded, sense or antisense, capable of hybridizing to a complementary nucleic acid by Watson-Crick base pairing. The nucleic acid sequences of the present invention may also include nucleotide analogs (e.g., BrdU) and non-phosphodiester internucleoside bonds (e.g., peptide nucleic acids (PNA) or thiodiester bonds). In particular, nucleic acid sequences may include, but are not limited to, DNA, RNA, cDNA, gDNA, ssDNA, dsDNA, or any combination thereof.
[0068] As used herein, an "effective amount" of a composition means a sufficient amount of the composition to provide the desired effect. The exact dosage required varies from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease (or underlying genetic defect) being treated, the specific compound used, the mode of administration, etc. Therefore, it is not possible to specify an exact "effective amount". However, one of ordinary skill in the art can determine an appropriate "effective amount" using only routine experimentation.
[0069] As used herein, "selectively binds" means that an MGS or MTS recognizes and physically interacts with its target (eg, a specific cell type) without significantly recognizing and interacting with other targets.
[0070] The term "homology percentage (%)" is used interchangeably with the term "identity percentage (%)" herein and refers to the level of nucleic acid or amino acid sequence identity when aligned with a wild-type sequence or a sequence of interest using a sequence alignment program. For example, as used herein, 80% homology means the same as 80% sequence identity determined by a defined algorithm, so that the homologs of a given sequence have greater than 80% sequence identity over the length of a given sequence. Exemplary levels of sequence identity include, but are not limited to, 80, 85, 90, 95, 98% or more sequence identity with a given sequence (e.g., any MTS sequence described herein). Exemplary computer programs that can be used to determine the identity between two sequences include, but are not limited to, the BLAST program suite disclosed on the Internet, such as BLASTN, BLASTX and TBLASTX, BLASTP and TBLASTN. See also Altschul et al., 1990 and Altschul et al., 1997. When evaluating a given nucleic acid sequence relative to nucleic acid sequences in GenBank DNA sequences and other public databases, a sequence search is typically performed using the BLASTN program. The BLASTX program is preferably used for searching the nucleotide sequences translated in all reading frames for the amino acid sequences in the GenBank protein sequences and other public databases. Both BLASTN and BLASTX are run with the default parameters of 11.0 for open gap penalty and 1.0 for extended gap penalty, and the BLOSUM-62 matrix is used. (See, for example, Altschul, SF, et al., Nucleic Acids Res. 25:3389-3402, 1997.) In order to determine " identity percentage (%) " between two or more sequences, the selected sequences are preferably compared using the CLUSTAL-W program in, for example, Mac Vector version 13.0.7, which operates with default parameters, including an open gap penalty of 10.0, an extended gap penalty of 0.1 and a BLOSUM 30 similarity matrix.
[0071] Substitutions, deletions, insertions or any combination thereof may be used to obtain a final derivative, variant or analog. Typically, these changes are made to a few nucleotides to minimize changes to the molecule. However, in some cases, larger changes may be tolerated.
[0072] Typically, the nucleotide identity between individual variant sequences can be at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. Therefore, a "variant sequence" can be a sequence with a specific identity to a parent or reference sequence of the present invention (e.g., a wild-type sequence), and has a common biological function, including but not limited to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the parent sequence specificity and / or activity. For example, a "variant sequence" can be a sequence comprising 1, 2, 3, 4 nucleotide base changes compared to a parent or reference sequence of the present invention, and has the same or improved biological function, specificity and / or activity of the parent sequence. Thus, a "variant sequence" may be a sequence having a specific identity with a parent sequence of the invention and having a common biological function, including but not limited to at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the specificity and / or activity of the parent sequence. A variant sequence may also have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the specificity and / or activity of a reference sequence (e.g., an MTS sequence).
[0073] As used herein, the term "optional" or "optionally" means that the subsequently described event, circumstance or material may or may not occur, or may exist or not exist, and that the description includes instances where said event, circumstance or material occurs or exists and instances where it does not occur or does not exist.
[0074] In this article, ranges can be expressed as from "about" a certain specific value and / or to "about" another specific value. When expressing such a range, it is also specifically considered and considered that what is disclosed is a range from a specific value and / or to another specific value, unless the context specifically indicates otherwise. Similarly, when a numerical value is expressed as an approximate value by using the antecedent "about", it should be understood that the specific value constitutes another specific embodiment that should be considered as disclosed, unless the context specifically indicates otherwise. It should also be understood that the endpoints of each range are important relative to the other endpoint and independently of the other endpoint, unless the context specifically indicates otherwise. Finally, it should be understood that all individual numerical values and sub-ranges of numerical values contained in the clearly disclosed range are also specifically envisioned and considered to be disclosed, unless the context specifically indicates otherwise. Regardless of whether some or all of these embodiments are clearly disclosed in a particular case, the foregoing applies.
[0075] Unless otherwise defined, all technical and scientific terms used herein have the meanings commonly understood by those of ordinary skill in the art to which the disclosed methods and compositions belong. Although any methods and materials similar or equivalent to those described herein may be used to implement or test the methods and compositions of the present disclosure, particularly useful methods, apparatuses and materials are described herein. Publications cited herein and materials cited therein are specifically incorporated herein by reference. All contents herein should not be construed as admitting that the present invention cannot be preceded by these publications by virtue of prior invention. It is not admitted that any reference constitutes prior art. The discussion of the references illustrates the claims of their authors, and the applicant reserves the right to question the accuracy and relevance of the cited documents. It should be clearly understood that although some publications are cited herein, such citation does not constitute an admission that any of these documents constitute part of the common general knowledge in the art.
[0076] Throughout the specification and claims of this specification, the word "comprise" and other forms of the word, such as "contain" and "comprises", means including but not limited to and is not intended to exclude, for example, other additives, components, integers or steps. In particular, in the method described including one or more steps or operations, it is specifically expected that each step includes the listed content (unless the step includes a restrictive term, such as "consisting of ..."), which means that each step is not intended to exclude, for example, other additives, components, integers or steps not listed in the step. B. Molecular Guidance System (MGS) Peptides
[0077] Disclosed herein are MGS peptides. In some aspects, MGS peptides can selectively bind to specific cell types. For example, disclosed herein are MGS peptides that can selectively bind to cells in the CNS, such as, but not limited to, neurons and microglia.
[0078] The present invention discloses the use of phage display for screening neuron-targeted molecular guide system ("MGS") peptides with high affinity and specificity, which can effectively deliver therapeutic molecules to neurons. This technology can quickly and effectively screen peptide sequences that can be used for neuron targeting. The neuron-targeted MGS peptides have a high affinity for neurons and can be internalized into neuronal cells. In addition, the neuron-targeted MGS peptides show selectivity in brain cells (such as astrocytes, microglia).
[0079] Neuron-targeted MGS peptides can be coupled with small molecules, nucleic acids and antibodies for therapeutic purposes. In addition, the general chemical properties of the peptide sequence can be modified to enhance neuron targeting sensitivity and specificity, as well as to perform dual or multiple targeting (e.g., in combination with peptides that invade the blood-brain barrier) in combination with other peptides. In addition, these neuron-targeting peptides have the ability to induce high neuron targeting sensitivity and specificity. Therefore, this neuron-targeting peptide is likely to become a guide system for treating neurological diseases such as Alzheimer's disease and Parkinson's disease.
[0080] Disclosed is an MGS peptide comprising an amino acid sequence of any sequence listed in SEQ ID NO: 1-8 as shown in Table 1. Table 1. Examples of MGS peptide sequences
[0081] Only monomeric MGS peptide sequences are shown in Table 1, however, MGS peptides can be used as multimers, such as dimers and tetramers. In some aspects, adding "-2" at the end of the peptide name refers to a dimeric MGS peptide. In some aspects, adding "-4" at the end of the peptide name refers to a tetrameric MGS peptide. For example, MGS_NOE3_V1-2 refers to a dimeric form of the GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1) sequence. In some aspects, MGS_NOE3_V1-4 refers to a tetrameric form of the GFHNVYPYTWGGFSDIDLMADEI (SEQID NO: 1) sequence. In some aspects, MGS_NOE3_V2-2 refers to a dimeric form of the Ac-GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 5) sequence. In some aspects, MGS_NOE3_V2-4 refers to the tetrameric form of the sequence Ac-GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 5) (tetramer). Thus, the same is true for EQRWVQMLHLQTRYAGEWPG (SEQ ID NO: 2), wherein MGS_Neuron1_V1-2 is a dimer form and MGS_Neuron1-V1-4 is a tetrameric form. Therefore, if MGS_Neuron1_V2, MGS_Neuron2_V1, MGS_Neuron2_V2, MGS2_V3 and MGS2_V4 are monomeric forms of the peptides shown in Table 1, then MGS_Neuron1_V2-2, MGS_Neuron2_V1-2, MGS_Neuron2_V2-2, MGS2-V3-2 and MGS2-V4-2 are dimer forms, and MGS_Neuron1_V2-4, MGS_Neuron2_V1-4, MGS_Neuron2_V2-4, MGS2_V3-4 and MGS2_V4-4 are tetramer forms.
[0082] In some aspects, one or more MGS peptides have at least 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% sequence identity with any of the sequences listed in SEQ ID NO: 1-8. In some aspects, one or more MGS peptides have 100% identity in the active portion of the peptide, wherein the active portion is the portion that retains its ability to target CNS cells. Thus, in some aspects, at least 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identity with any MGS peptide occurs outside the active portion.
[0083] In some aspects, the MGS peptide can be modified. In some aspects, the modified MGS peptide includes an optimized peptide or a stabilized peptide. In some aspects, the MTS peptide can be optimized. By modifying a single parent peptide sequence, an optimized peptide can be obtained. These modifications can be used to identify the essential amino acids required to enter CSF across the blood in the parent sequence. These modifications can be obtained by a combination of alanine scanning and truncating the amino terminal region and the C terminal region of the parent peptide. PEG can protect the C-terminus of the MGS peptide, provide a joint between the peptide and the carrier molecule attached by the C-terminal cysteine, and enhance the solubility of the MGS peptide. Modification at the amino terminal by acetylation (CH3CO-) and / or d-amino acid (e.g., d(Leu)) can prevent degradation by peptidases in the blood. For all MGS peptides, there is no uniform length of optimized peptides that can be applied, and all changes can be tested to confirm their effects on peptide absorption and stability. Therefore, in some aspects, the MGS peptide can have an N-terminal protecting group. In some aspects, the N-terminal protecting group can be any substance that prevents proteases from cutting amino acids from the N-terminus. In some aspects, the MGS peptide disclosed herein can be modified by acetylation of the N-terminus. In some aspects, the N-terminal protecting group is an acetyl group (Ac=CH3CO). In some aspects, the N-terminal protecting group can be, but is not limited to, PEG, formyl, CH3-(CH)n-CO, a fluorophore, a fatty acid, an alkylamine, an aryl, a carbohydrate, a sulfonamide, or a carbamate.
[0084] In some aspects, the MGS peptide disclosed herein can be chemically coupled to another MGS peptide, a carrier and / or another joint. In some aspects, the chemical conjugate can be polyethylene glycol (PEG). Therefore, in some aspects, the MGS peptide disclosed herein can be pegylated. In some aspects, the number of PEG units can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 18, 20, 22, 24 or more. In some aspects, the number of PEG units can have a sufficient length to separate one or more MGS peptides from the carrier, thereby preventing any spatial interference between one or more MGS peptides and the carrier. Therefore, in some aspects, the MGS peptide disclosed herein may also include a joint. For example, a joint and a chemical conjugate can be used interchangeably. In some aspects, the joint is located at the C-terminus of the MGS peptide. In one aspect, the MGS peptide disclosed herein comprises one or more sequences listed in SEQ ID NO: 1-8, wherein SEQ ID NO: 1-8 can be chemically coupled to another joint of PEG or C-terminus. In some aspects, a linker can connect two or more MGS peptides. In some aspects, a linker can be coupled to a carrier. For example, an MGS peptide comprising a linker can comprise the structure shown in Figure 3, wherein X is an MGS peptide and R is a reactive group that can be coupled to a carrier or another linker.
[0085] In some aspects, the linker can be any of those described herein. For example, the linker can be of any length that enables coupling of the MGS peptide to other substances and prevents steric hindrance.
[0086] In some aspects, the linker comprises a PEG linker, an alkyl linker, a maleimide linker, an amide linker, a peptide linker, an amide linker, an aryl linker, a dibenzocyclooctyne linker, an azide linker, a triazole linker, a bisbenzazacyclooctyne, 8,9-dihydro-1H-dibenzo[1,2,3]triazolo[4,45-d]azocine, or a combination thereof.
[0087] In some respects, Figure 1 and Figure 2 An example structure of an MGS peptide is shown. Figure 1 The structure of the MGS2_V4 peptide sequence is shown: CH3CO-YAAWPASGAWT (SEQ ID NO: 8). Figure 2 The structure of the MGS_NOE3_V2 peptide sequence is shown. CH3-CO-GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 5).
[0088] In some aspects, the disclosed MGS peptides can be dimers, in which two MGS peptides are coupled together. An example of the structure of a dimer MGS core is as follows: Figure 3A In some aspects, the two MGS peptides can be the same MGS peptide or two different MGS peptides. In some aspects, the two MGS peptides are coupled via a linker.
[0089] In some aspects, the disclosed MGS peptides can be tetramers, in which four MGS peptides are coupled together. An example of the structure of a tetrameric MGS core is as follows: Figure 3B In some aspects, the four MGS peptides can be the same MGS peptides or a combination of different MGS peptides. In some aspects, the four MGS peptides are coupled via a linker.
[0090] In some aspects, the reactive groups can be, but are not limited to: carboxylic acids, acyl halides, sulfonyl halides, chloroformates, aldehydes, alkynes, alkynes (without acetylenic hydrogens), amides and imides, amines, phosphines and pyridines, anhydrides, azo, dinitrogen, azide, hydrazines and azides, carbamates, epoxides, esters, sulfates, phosphates, thiophosphates and borates, halogenated organic compounds, isocyanates and isothiocyanates, ketones, oximes, sulfides (organic). C. Molecular Transport System (MGS) Peptides
[0091] Transporting cargo across the blood-cerebrospinal fluid barrier provides a unique opportunity to affect the transport of cargo (e.g., drugs and macromolecules) into the CNS. Accordingly, disclosed herein are peptides that target the CNS, generally referred to as molecular transport system (MTS) peptides.
[0092] Disclosed herein are MTS peptides. Disclosed are MTS peptides comprising an amino acid sequence of any of the sequences listed in SEQ ID NOs: 9-14 as shown in Table 2. Table 2. Exemplary MTS peptide sequences
[0093] Only monomeric MTS peptide sequences are shown in Table 2, however, MTS peptides can be used as multimers, such as dimers and tetramers. In some aspects, adding "-2" at the end of the peptide name refers to a dimeric MTS peptide. For example, MTS1_V2-2 refers to a dimeric form of the Ac-DAYKLQTSLDWQMWNP (SEQ ID NO: 10) sequence. In some aspects, MTS2-V1-2 and MTS3-V1-2 are dimeric forms of MTS2-V1 and MTS3-V1, respectively. In some aspects, when further optimizations such as lipidation are added, it will be referred to as the next version or "V". For example, MTS3-V2-2 is a lipidated form of MTS3-V1-2.
[0094] In some aspects, one or more MTS peptides have at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity with any of the sequences listed in SEQ ID NOs: 9-14. In some aspects, one or more MTS peptides have 100% identity in the active portion of the peptide, wherein the active portion is the portion that retains its ability to cross the blood into the CSF. Thus, in some aspects, at least 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% identity with any MTS peptide occurs outside the active portion.
[0095] In some aspects, the MTS peptide can be modified. In some aspects, modifying the MTS peptide includes optimizing the peptide or stabilizing the peptide.
[0096] In some aspects, the MTS peptide can be stabilized so that the MTS peptide remains intact (e.g., does not degrade) during synthesis and / or storage. In some aspects, the MTS peptide can be stabilized by converting glycine to alanine. In some aspects, the glycine at position 2 of SEQ ID NO: 9 or 10 can be stabilized by changing it to alanine.
[0097] In some aspects, the MTS peptide can be optimized. By modifying a single parent peptide sequence, an optimized peptide can be obtained. These modifications can be used to identify the essential amino acids required for the parent sequence to cross the blood and enter the CSF. These modifications can be obtained by a combination of alanine scanning and truncating the amino terminal region and the C terminal region of the parent peptide. PEG12 can protect the C-terminus of the MTS peptide, provide a linker between the peptide and the carrier molecule attached by the C-terminal cysteine, and enhance the solubility of the MTS peptide. Modification of the N-terminus of the MTS peptide by acetylation (CH3CO-) and / or d-amino acid (e.g., d(Leu)) can prevent degradation by peptidases in the blood. For all MTS peptides, there is no uniform length of optimized peptides that can be applied, and all changes can be tested to confirm their effects on peptide absorption and stability.
[0098] In some aspects, the MTS peptide disclosed herein can have an N-terminal protecting group. In some aspects, the N-terminal protecting group can be any substance that prevents proteases from cutting amino acids from the N-terminus. In some aspects, the MTS peptide disclosed herein can be modified by acetylation of the N-terminus. In some aspects, the N-terminal protecting group is an acetyl group. Therefore, in some aspects, the MTS peptide disclosed herein can be acetylated. In some aspects, the N-terminal protecting group can be, but is not limited to, PEG, formyl, CH3-(CH2)n-CO, a fluorophore, a fatty acid, an alkylamine, a sulfonamide, an aryl, a carbohydrate, a D-amino acid, or a carbamate.
[0099] In some aspects, the MTS peptide disclosed herein can be chemically coupled to another MTS peptide, a carrier and / or another linker. In some aspects, the chemical conjugate can be polyethylene glycol (PEG). Therefore, in some aspects, the MTS peptide disclosed herein can be pegylated. In some aspects, the number of PEG units can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 18, 20, 22, 24 or more. In some aspects, the number of PEG units can have a sufficient length to separate one or more MTS peptides from the carrier, thereby preventing any spatial interference between one or more MTS peptides and the carrier. Therefore, in some aspects, the MTS peptide disclosed herein may also include a linker. For example, a linker and a chemical conjugate can be used interchangeably. In some aspects, the linker is located at the C-terminus of the MTS peptide. In one aspect, the MTS peptide disclosed herein comprises one or more sequences listed in SEQ ID NO: 9-14, wherein SEQ ID NO: 9-14 can be acetylated at the N-terminus and can be chemically coupled to PEG or another linker at the C-terminus. In some aspects, the linker can connect two or more MTS peptides. In some aspects, the linker can be coupled to a carrier. For example, the MTS peptide comprising a linker can comprise the structure shown in Figure 3, wherein X is an MTS peptide and R is a reactive group that can be coupled to a carrier or another linker.
[0100] In one aspect, the MTS peptide disclosed herein can be truncated. In some aspects, the MTS peptide disclosed herein is truncated to eliminate all amino acids except the active portion of the MTS peptide. In some aspects, the active portion of the MTS peptide can be used in the disclosed compositions and methods. In some aspects, techniques well known in the art can be used to determine the active portion, such as alanine scanning or truncation studies. The active portion of the MTS peptide is a portion that retains its ability to cross the blood and enter the CSF. For example, up to four amino acids at the N-terminus of SKETYSMNAQRQHERS (SEQ ID NO: 13) can be truncated. In some aspects, the amino acid sequence YSMNAQRQHERS (SEQ ID NO: 16) is the active portion of SKETYSMNAQMQHERS (SEQ ID NO: 13).
[0101] In some aspects, stabilized or optimized variants of the MTS peptides disclosed herein are disclosed.
[0102] Examples of MTS peptides are Figure 4 shown. Figure 4 A shows an example of the MTS peptide Ac-DAYKLQTSLDWQMWNP (SEQ ID NO: 10), also referred to as MTS1_V2. Figure 4B shows an example of the MTS peptide Ac-DAYKLQTSLDWQMWNP (SEQ ID NO: 12), also referred to as MTS2_V1. Figure 4 C shows an example of the MTS peptide Ac-SKETYSMNAQRQHERS (SEQ ID NO: 14), also known as MTS3_V1.
[0103] In some aspects, the disclosed MTS peptides can be dimers, in which two MTS peptides are coupled together. An example of the structure of a dimeric MTS core is as follows: Figure 3A In some aspects, the two MTS peptides can be the same MTS peptide or two different MTS peptides. In some aspects, the two MTS peptides are coupled together via a linker.
[0104] In some aspects, the reactive groups can be, but are not limited to: carboxylic acids, acyl halides, sulfonyl halides, chloroformates, aldehydes, alkynes, alkynes (without acetylenic hydrogens), amides and imides, amines, phosphines and pyridines, anhydrides, azos, dinitrogens, azides, hydrazines and azides, carbamates, epoxies, esters, sulfates, phosphates, thiophosphates and borates, halogenated organic compounds, isocyanates and isothiocyanates, ketones, oximes, sulfides (organic). D.Connector
[0105] Linkers are disclosed. In some aspects, a linker can couple or connect two or more MGS peptides, two or more MTS peptides, two or more linkers, or linkers or peptides to a carrier.
[0106] In some aspects, the linker that couples two or more MGS peptides or two or more MTS peptides together can be called a dimer core (if connected to two peptides) or a tetramer core (if connected to four peptides). Figure 3 shows examples of structures of dimer cores and tetramer cores. In Figure 3, the linker comprises PEG12, however, in some aspects, PEG of any length can be used. For example, any one of PEG1-PEG30 can be used. In some aspects, PEG with a length of 1-5000 can be used. In some aspects, any linker can be used to replace the PEG12 of a dimer core or a tetramer core.
[0107] Disclosed are linkers comprising at least one reactive group capable of binding to the C-terminus of a peptide; and at least one other reactive group capable of chemically reacting with a moiety.
[0108] In some aspects, the length of the joint is up to PEG5000. About PEG joints, in some aspects, the joint length can be a single PEG, up to 5000 PEG. In some aspects, the joint between peptide and carrier can be longer than the joint between two MGS or MTS peptides. In some aspects, the joint includes two to four PEG joints. In some aspects, the joint with two PEG joints can be called a dimer core. In some aspects, the joint with four PEG joints can be called a tetramer core.
[0109] In some aspects, the linker comprises at least two PEG linkers and a reactive group between at least two of the PEG linkers. In some aspects, the reactive group connects at least two PEG linkers.
[0110] In some aspects, the linker comprises an amino acid, a peptide, an alkyl, a maleimide, a thiol, a hydrazone or an amide. In some aspects, the amino acid can be a modified amino acid. For example, the modified amino acid can be a functionalized lysine, a functionalized cysteine, a functionalized glutamic acid or a functionalized aspartic acid. In some aspects, the linker comprises biotin.
[0111] In some aspects, the linker comprises the following structure: Wherein, X is a peptide and R is a reactive group capable of chemically reacting with a moiety. In some aspects, X can be an MGS peptide or an MTS peptide. In some aspects, this structure can be referred to as a dimer core because it can connect two peptides.
[0112] In some aspects, the linker also includes a lipid portion. For example, one of the R groups from the dimer core can react with the lipid portion. Therefore, in some aspects, the linker includes the following structure: Wherein, X is a peptide and R is a reactive group capable of chemically reacting with a moiety. In some aspects, X can be an MGS peptide or an MTS peptide. In some aspects, X can be an MGS peptide or an MTS peptide.
[0113] In some aspects, the linker comprises the following structure: Wherein, X is a peptide and R is a reactive group capable of chemically reacting with a moiety. In some aspects, X can be an MGS peptide or an MTS peptide. In some aspects, this structure can be referred to as a tetramer core because it can connect four peptides. Another example of a tetramer core includes the following structure: Wherein, X is a peptide and R is a reactive group capable of chemically reacting with a moiety. In some aspects, X can be an MGS peptide or an MTS peptide. In some aspects, the reactive groups can be, but are not limited to: carboxylic acids, acyl halides, sulfonyl halides, chloroformates, aldehydes, alkynes, alkynes (without acetylenic hydrogens), amides and imides, amines, phosphines and pyridines, anhydrides, azo, dinitrogen, azide, hydrazines and azides, carbamates, epoxides, esters, sulfates, phosphates, thiophosphates and borates, halogenated organic compounds, isocyanates and isothiocyanates, ketones, oximes, sulfides (organic).
[0114] In some aspects, part can be a carrier. In some aspects, carrier can be but not limited to dye, imaging agent, therapeutic agent, protein, nucleic acid, amino acid, peptide, lipid, antibody, radionuclide, carbohydrate or nanoparticle. In some aspects, part can be a joint. Therefore, in some aspects, a joint comprising multiple joints is disclosed. For example, if the joint is a tetramer core (i.e., the first joint), the tetramer core can include a part as the second joint. In some aspects, the second joint can include the same element or different elements as the tetramer core. In some aspects, the second joint couples the tetramer core (i.e., the third joint) to the dimer core.
[0115] In some aspects, any of the first, second, or third linkers can include an amino acid, a peptide, an alkyl, a maleimide, a thiol, a hydrazone, a dibenzocyclooctyne, an azide, or an amide. E. Composition
[0116] Disclosed are compositions comprising one or more of the disclosed MGS peptides, MTS peptides, linkers, and / or combinations thereof.
[0117] Disclosed are compositions comprising at least one MGS peptide coupled to at least one MTS peptide, wherein the MGS peptide comprises the amino acid sequence GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1); EQRWVQMLHLQTRYAGEWPG (SEQ ID NO: 2); FQHNPFPYTYSMEDTVEIK (SEQ ID NO: 3); or YAAWPASGAWT (SEQ ID NO: 4).
[0118] Disclosed are compositions comprising two or more MGS peptides coupled to two or more MTS peptides, wherein the two or more MGS peptides comprise the amino acid sequence GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1); EQRWVQMLHLQTRYAGEWPG (SEQ ID NO: 2); FQHNPFPYTYSMEDTVEIK (SEQ ID NO: 3); or YAAWPASGAWT (SEQ ID NO: 4).
[0119] In some aspects, the two or more MGS peptides are four MGS peptides. Thus, for example, a composition comprising four MGS peptides coupled to at least two MTS peptides is disclosed, wherein the four MGS peptides comprise the amino acid sequence GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1); EQRWVQMLHLQTRYAGEWPG (SEQ ID NO: 2); FQHNPFPYTYSMEDTVEIK (SEQ ID NO: 3); or YAAWPASGAWT (SEQ ID NO: 4).
[0120] Disclosed is a composition comprising four MGS peptides coupled to two MTS peptides, wherein the four MGS peptides comprise the amino acid sequence GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1); EQRWVQMLHLQTRYAGEWPG (SEQ ID NO: 2); FQHNPFPYTYSMEDTDVEIK (SEQ ID NO: 3); or YAAWPASGAWT (SEQ ID NO: 4); and the two MTS peptides comprise the amino acid sequence DAYKLQTSLDWQMWNP (SEQ ID NO: 9); FPSWTSKNQQWTNQRQ (SEQ ID NO: 11); or SKETYSMNAQRQHERS (SEQ ID NO: 13).
[0121] In some aspects, two or more MGS peptides are the same MGS peptides. For example, if there are four MGS peptides in the composition, in some aspects, all four MGS peptides are the same MGS peptides. In some aspects, at least one MGS peptide is different from the other MGS peptides. In some aspects, each MGS peptide is different from each other.
[0122] In some aspects, two or more MTS peptides are the same MTS peptide. For example, in some aspects, there are two MTS peptides in the disclosed composition, and both MTS peptides are the same MTS peptide. In some aspects, there are two MTS peptides in the disclosed composition, and each peptide is different from each other.
[0123] In some aspects, the MGS peptide and / or MTS peptide has an N-terminal protecting group. In some aspects, the N-terminal protecting group is an acetyl group.
[0124] In some aspects, the disclosed composition may also include one or more joints. In some aspects, the disclosed composition may also include a first joint. In some aspects, the first joint is attached to the C-terminus of the MGS peptide. In some aspects, the first joint may be any joint described herein. In some aspects, the first joint may include a PEG joint, an alkyl joint, a maleimide joint, an amide joint, a peptide joint, an amide joint, an aryl joint, a dibenzocyclooctyne joint, an azide joint, a triazole joint, a bisbenzazacyclooctyne, 8,9-dihydro-1H-dibenzo[1,2,3]triazolo[4,45-d]azacyclooctyne or a combination thereof. In some aspects, the first joint may connect the MGS peptide to another MGS peptide, or connect the MGS polypeptide to a carrier, or connect the MGS peptide to another joint. In some aspects, the first joint may include one or more structures shown in Figure 3. For example, each MGS peptide may be attached to a joint, such as PEG (any length). The individual MGS peptide-PEGs can then be linked using one or more amino acids, modified amino acids, or linkers that can produce a dimer or tetramer core as described herein.
[0125] In some aspects, the composition can also include a second joint. In some aspects, the second joint is attached to the first joint. In some aspects, the second joint is also attached to the third joint. Therefore, in some aspects, the composition also includes a third joint.
[0126] In some aspects, the third joint is attached to the second joint. In some aspects, the third joint is attached to the C-terminus of the MTS peptide. In some aspects, the third joint can be any joint described herein. In some aspects, the third joint may include a PEG joint, an alkyl joint, a maleimide joint, an amide joint, a peptide joint, an aryl joint, a dibenzocyclooctyne joint, an azide joint, a triazole joint, a bisbenzazacyclooctyne, 8,9-dihydro-1H-dibenzo [1,2,3] triazolo [4,45-d] azacyclooctyne or a combination thereof. In some aspects, the third joint can connect the MTS peptide to another MTS peptide, or connect the MTS polypeptide to a carrier, or connect the MTS peptide to another joint. In some aspects, the third joint may include one or more structures shown in Figure 3. For example, each MTS peptide can be attached to a joint, such as PEG (any length). Then, one or more amino acids, modified amino acids, or joints that can produce dimers or tetramer cores described herein can be used to connect each MTS peptide-PEG.
[0127] In some aspects, the first joint and / or the second joint and / or the third joint include polyethylene glycol (PEG) joints, alkyl joints, maleimide joints, disulfide joints, peptide joints, amide joints, aryl joints, dibenzocyclooctyne joints, azide joints, triazole joints, bisbenzazacyclooctyne, 8,9-dihydro-1H-dibenzo [1,2,3] triazolo [4,45-d] azacyclooctene or a combination thereof. In some aspects, the first, second and / or third joints include PEG joints. In some aspects, PEG joints of any length can be used. For example, any PEG1-PEG30 can be used. In some aspects, a PEG with a length of 1-5000 can be used.
[0128] In some aspects, the composition may also include a carrier. In some aspects, the carrier may be, but is not limited to, a dye, an imaging agent, a therapeutic agent, a protein, a nucleic acid, an amino acid, a peptide, a lipid, a small molecule, an antibody, a radionuclide, a carbohydrate, or a nanoparticle. For example, in some aspects, the carrier is an imaging agent, an antibody, and / or an siRNA. In some aspects, the carrier is attached to a first joint, a second joint, and / or a third joint. In some aspects, the disclosed composition may also include one or more carriers. In some aspects, one or more joints may include a carrier.
[0129] In some aspects, the MTS peptide is any MTS peptide described in the full text. In some aspects, the MTS peptide targets the central nervous system. In some aspects, the MTS peptide comprises an amino acid sequence of any one of SEQ ID NO:9-14. In some aspects, the MTS peptide comprises the amino acid sequence DAYKLQTSLDWQMWNP (SEQ ID NO:9); FPSWTSKNQQWTNKRQ (SEQ ID NO:11); or SKETYSMNAQRQHERS (SEQ ID NO:13). In some aspects, the MTS peptide comprises an N-terminal protecting group. In some aspects, the N-terminal protecting group can be any substance that prevents proteases from cleaving amino acids from the N-terminus. In some aspects, the N-terminal protecting group is an acetyl group. In some aspects, the N-terminal protecting group can be, but is not limited to, PEGylation, formyl, CH3-(CH2)n-CO, aryl, carbohydrate, D-amino acid, fluorophore, fatty acid, alkylamine, arylamine, sulfonamide or carbamate.
[0130] In some aspects, the composition includes two MTS peptides. In some aspects, the two MTS peptides are linked by a dimer core as described throughout.
[0131] A composition comprising the following components is disclosed: an MGS peptide comprising the amino acid sequence GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1); EQRWVQMLHLQTRYAGEWPG (SEQ ID NO: 2); or FQHNPFPYTYSMEDTDVEIK (SEQ ID NO: 3); a first linker comprising (i) at least one reactive group capable of binding to the C-terminus of the peptide; (ii) at least one other reactive group capable of chemically reacting with a portion; a second linker; a third linker comprising (i) at least one reactive group capable of binding to the C-terminus of the peptide; (ii) at least one other reactive group capable of chemically reacting with a portion; and an MTS peptide comprising the amino acid sequence DAYKLQTSLDWQMWNP (SEQID NO: 9); FPSWTSKNQQWTNQRQ (SEQ ID NO: 11); or SKETYSMNAQRQHERS (SEQ ID NO: 13).
[0132] In some aspects, the C-terminus of the MGS peptide comprising the amino acid sequence GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1), EQRWVQMLHLQTRYAGEWPG (SEQ ID NO: 2), or FQHNPYPYTYSMEDDVEIK (SEQ ID NO: 3) is attached to the first linker. In some aspects, the first linker is attached to the second linker. In some aspects, the second linker is attached to the third linker. In some aspects, the third linker is attached to the C-terminus of a peptide (MTS) comprising the amino acid sequence DAYKLQTSLDWQMWNP (SEQ ID NO: 9), FPSWTSKNQQWTNKRQ (SEQ ID NO: 11), or SKETYSMNAQRQHERS (SEQ ID NO: 13).
[0133] Thus, in some aspects, a composition comprising the following components is disclosed: an MGS peptide comprising the amino acid sequence GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1), EQRWVQMLHLQTRYAGEWPG (SEQ ID NO: 2), or FQHNPFPYTYSMEDTDVEIK (SEQ ID NO: 3), wherein the MGS peptide is reactively attached to a first linker, wherein the first linker is attached to a second linker, wherein the second linker is attached to a third linker, wherein the third linker is attached to the C-terminus of a peptide (MTS) comprising the amino acid sequence DAYKLQTSLDWQMWNP (SEQ ID NO: 9); FPSWTSKNQQWTNQRQ (SEQ ID NO: 11); or SKETYSMNAQRQHERS (SEQ ID NO: 13).
[0134] In some aspects, the composition comprises the following structure: Wherein, X is a MGS peptide, X' is a MTS peptide, and R is a reactive group capable of chemically reacting with a moiety. In some aspects, the MGS peptide is any of those described herein. In some aspects, the MGS peptide comprises an amino acid sequence of any of the sequences listed in SEQ ID NO: 1-8 as shown in Table 1. In some aspects, the MGS peptide is any of those described herein. In some aspects, the MTS peptide comprises an amino acid sequence of any of the sequences listed in SEQ ID NO: 9-14 as shown in Table 2.
[0135] In some aspects, the composition comprises the following structure: Wherein, X is an MTS peptide, X' is an MGS peptide, and R is a reactive group capable of chemically reacting with a moiety. In some aspects, the MGS peptide is any of those described herein. In some aspects, the MGS peptide comprises an amino acid sequence of any of the sequences listed in SEQ ID NO: 1-8 as shown in Table 1. In some aspects, the MGS peptide is any of those described herein. In some aspects, the MTS peptide comprises an amino acid sequence of any of the sequences listed in SEQ ID NO: 9-14 as shown in Table 2.
[0136] In some aspects, the composition comprises the following structure: Wherein, X' is an MTS peptide, X is an MGS peptide, and R is a reactive group capable of chemically reacting with an amino acid. In some aspects, the MGS peptide is any of those described herein. In some aspects, the MGS peptide comprises an amino acid sequence of any of the sequences listed in SEQ ID NO: 1-8 as shown in Table 1. In some aspects, the MGS peptide is any of those described herein. In some aspects, the MTS peptide comprises an amino acid sequence of any of the sequences listed in SEQ ID NO: 9-14 as shown in Table 2.
[0137] In some aspects, the reactive groups can be, but are not limited to: carboxylic acids, acyl halides, sulfonyl halides, chloroformates, aldehydes, alkynes, alkynes (without acetylenic hydrogens), amides and imides, amines, phosphines and pyridines, anhydrides, azo, dinitrogen, azide, hydrazines and azides, carbamates, epoxides, esters, sulfates, phosphates, thiophosphates and borates, halogenated organic compounds, isocyanates and isothiocyanates, ketones, oximes, sulfides (organic).
[0138] Pharmaceutical compositions are disclosed. Therefore, the disclosed compositions may further comprise a pharmaceutically acceptable carrier. A composition is disclosed, comprising an MGS peptide and a pharmaceutically acceptable carrier, wherein the MGS peptide comprises an amino acid sequence of any sequence listed in SEQ ID NO: 1-8 as shown in Table 1. A composition is disclosed, comprising an MTS peptide and a pharmaceutically acceptable carrier, wherein the MTS peptide comprises an amino acid sequence of any sequence listed in SEQ ID NO: 9-14 as shown in Table 2. A composition is disclosed, comprising four MGS peptides coupled to two MTS peptides and a pharmaceutically acceptable carrier, wherein the four MGS peptides comprise the amino acid sequence GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1), EQRWVQMLHLQTRYAGEWPG (SEQ ID NO: 2), FQHNPFPYTYSMEDTDVEIK (SEQ ID NO: 3) or YAAWPASGAWT (SEQ ID NO: 4); wherein the two MTS peptides comprise the amino acid sequence DAYKLQTSLDWQMWNP (SEQ ID NO: 9), FPSWTSKNQQWTNQRQ (SEQID NO: 11) or SKETYSMNAQRQHERS (SEQ ID NO: 13). 1. Delivery of the composition
[0139] In the methods described herein, the delivery (or administration) of the peptides or compositions disclosed herein can be carried out by a variety of mechanisms. As described above, the compositions disclosed herein include any one or more peptides described herein, which can be used to prepare compositions that can also include a carrier (such as a pharmaceutically acceptable carrier). For example, a pharmaceutical composition comprising a peptide disclosed herein and a pharmaceutically acceptable carrier is disclosed.
[0140] For example, the compositions described herein may include a pharmaceutically acceptable carrier. "Pharmaceutically acceptable" means selecting a material or carrier to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as is well known to those skilled in the art. Examples of carriers include dimyristoylphosphatidylcholine (DMPC), phosphate buffered saline, or multivesicular liposomes. For example, PG: PC: cholesterol: peptide or PC: peptide can be used as a carrier of the present invention. Other suitable pharmaceutically acceptable carriers and their preparations are described in Remington: The Science and Practice of Pharmacy (19th edition), editor A. R. Gennaro, Mack Publishing Company, Easton, Pennsylvania, 1995. Typically, an appropriate amount of pharmaceutically acceptable salt is used in the formulation to make the formulation isotonic. Other examples of pharmaceutically acceptable carriers include, but are not limited to, saline, Ringer's solution, and dextrose solution. The pH of the solution may be from about 5 to about 8, or from about 7 to about 7.5. Other carriers include sustained release formulations, such as semipermeable matrices of solid hydrophobic polymers containing the composition, which are in the form of shaped articles, such as films, stents (implanted into blood vessels during angioplasty), liposomes, or microparticles. It will be apparent to those skilled in the art that certain carriers may be more preferred, depending, for example, on the route of administration and the concentration at which the composition is administered. These are most typically standard carriers for administering drugs to humans, including solutions such as sterile water, saline, and physiological pH buffered solutions.
[0141] The pharmaceutical composition may also include a carrier, a thickener, a diluent, a buffer, a preservative, etc., as long as the expected activity of the polypeptide, peptide, nucleic acid, or carrier of the present invention is not impaired. The pharmaceutical composition may also include one or more active ingredients (in addition to the composition of the present invention), such as an antimicrobial, an anti-inflammatory, an anesthetic, etc. The pharmaceutical composition may be administered in a variety of ways, depending on whether local or systemic treatment is desired, and the area of treatment.
[0142] Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous vehicles include water, alcoholic / aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's solution or fixed oils. Intravenous vehicles include fluid and nutritional supplements, electrolyte supplements (e.g., those based on Ringer's dextrose), etc. Preservatives and other additives may also be present, for example, antimicrobial agents, antioxidants, chelating agents, and inert gases, etc.
[0143] Preparations for topical administration may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
[0144] Compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or adhesives may be required. Some compositions may be given as pharmaceutically acceptable acid or base addition salts, by reacting with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid and phosphoric acid and organic acids, such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid and fumaric acid, or by reacting with inorganic bases such as sodium hydroxide, ammonium hydroxide, potassium hydroxide and organic bases such as mono-, di-, trialkyl and arylamines and substituted ethanolamines.
[0145] The disclosed delivery technologies can be applied not only to the disclosed compositions, but also to the disclosed nucleic acid sequences and vectors. F. Methods of delivering cargo
[0146] Disclosed are methods of transporting a cargo to the central nervous system of a subject, comprising administering one or more compositions disclosed herein to a subject in need thereof, wherein a peptide coupled to the cargo enters the central nervous system.
[0147] In some aspects, the carrier can be, but is not limited to, a dye, an imaging agent, a therapeutic agent, a protein, a nucleic acid, an amino acid, a peptide, a lipid, a small molecule, an antibody, a radionuclide, a carbohydrate, or a nanoparticle. For example, in some aspects, the carrier is an imaging agent, an antibody, and / or a siRNA.
[0148] In some aspects, the composition and cargo enter the choroid plexus. In some aspects, the composition and cargo enter the cerebrospinal fluid (CSF). In some aspects, the CSF transports the composition and cargo throughout the central nervous system.
[0149] In some aspects, the MTS peptide allows the composition to pass through the blood-brain barrier and enter the central nervous system. In some aspects, the MGS peptide targets the cargo to a specific CNS cell. In some aspects, the CNS cell is a neuronal cell or a microglial cell.
[0150] In some aspects, the cargo remains functionally active within the central nervous system.
[0151] In some aspects, administration is intravenous or intrathecal.In some aspects, any delivery method described herein can be used.
[0152] In some aspects, the composition can be a composition comprising four MGS peptides coupled to two MTS peptides, wherein the four MGS peptides comprise the amino acid sequence GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1), EQRWVQMLHLQTRYAGEWPG (SEQ ID NO: 2), FQHNPFPYTYSMEDTDVEIK (SEQ ID NO: 3) or YAAWPASGAWT (SEQ ID NO: 4); wherein the two MTS peptides comprise the amino acid sequence DAYKLQTSLDWQMWNP (SEQ ID NO: 9), FPSWTSKNQQWTNQRQ (SEQ ID NO: 11) or SKETYSMNAQRQHERS (SEQ ID NO: 13).
[0153] As described in the full text, the composition may also include one or more joints. In some aspects, the disclosed composition may also include a first joint. In some aspects, the first joint is attached to the C-terminus of the MGS peptide. In some aspects, the first joint may be any joint described herein. In some aspects, the first joint may include a PEG joint, an alkyl joint, a maleimide joint, an amide joint, a peptide joint, an amide joint, an aryl joint, a dibenzocyclooctyne joint, an azide joint, a triazole joint, a bisbenzazacyclooctyne, 8,9-dihydro-1H-dibenzo[1,2,3]triazolo[4,45-d]azacyclooctyne or a combination thereof. In some aspects, the first joint may connect the MGS peptide to another MGS peptide, or connect the MGS polypeptide to a carrier, or connect the MGS peptide to another joint. In some aspects, the first joint may include one or more structures shown in Figure 3. For example, each MGS peptide may be attached to a joint, such as PEG (any length). The individual MGS peptide-PEGs can then be linked using one or more amino acids, modified amino acids, or linkers that can produce a dimer or tetramer core as described herein.
[0154] In some aspects, the composition may further include a second joint. In some aspects, the second joint is attached to the first joint. In some aspects, the second joint is also attached to the third joint. Thus, in some aspects, the composition may further include a third joint.
[0155] In some aspects, the third joint is attached to the second joint. In some aspects, the third joint is attached to the C-terminus of the MTS peptide. In some aspects, the third joint can be any joint described herein. In some aspects, the third joint may include a PEG joint, an alkyl joint, a maleimide joint, an amide joint, an aryl joint, a peptide joint, a dibenzocyclooctyne joint, an azide joint, a triazole joint, a bisbenzazacyclooctyne, 8,9-dihydro-1H-dibenzo [1,2,3] triazolo [4,45-d] azacyclooctyne or a combination thereof. In some aspects, the third joint can connect the MTS peptide to another MTS peptide, or connect the MTS polypeptide to a carrier, or connect the MTS peptide to another joint. In some aspects, the third joint can include one or more structures shown in Figure 3. For example, each MTS peptide can be attached to a joint, such as PEG (any length). Then, one or more amino acids, modified amino acids, or joints that can produce dimers or tetramer cores described herein can be used to connect each MTS peptide-PEG.
[0156] In some aspects, the first joint and / or the second joint and / or the third joint include polyethylene glycol (PEG) joints, alkyl joints, maleimide joints, disulfide joints, peptide joints, amide joints, aryl joints, dibenzocyclooctyne joints, azide joints, triazole joints, bisbenzazacyclooctyne, 8,9-dihydro-1H-dibenzo [1,2,3] triazolo [4,45-d] azacyclooctene or a combination thereof. In some aspects, the first, second and / or third joints include PEG joints. In some aspects, PEG joints of any length can be used. For example, any PEG1-PEG30 can be used. In some aspects, a PEG with a length of 1-5000 can be used.
[0157] In some aspects, the carrier is attached to the first joint, the second joint and / or the third joint. In some aspects, the disclosed composition can include one or more carriers. In some aspects, one or more joints can include a carrier.
[0158] In some aspects, the MGS peptide, the MTS peptide, or both are protected at the N-terminus. In some aspects, the MGS peptide, the MTS peptide, or both include N-terminal acetylation. Therefore, in some aspects, the MGS peptide or the MTS peptide can be any one of Table 1 and / or Table 2. G. Treatment methods
[0159] Disclosed are methods of treating a central nervous system disease or injury in a subject, comprising administering to a subject in need thereof one or more compositions disclosed herein, wherein the cargo is a central nervous system disease or injury therapeutic agent.
[0160] In some aspects, the central nervous system disease or injury is Parkinson's disease, Alzheimer's disease, glioblastoma, amyotrophic lateral sclerosis, multiple sclerosis or traumatic brain injury. Therefore, in some aspects, the central nervous system disease therapeutic agent is an antibody (e.g., monoclonal, polyclonal, bispecific), gene therapy, compound, nucleic acid sequence, small molecule, ribonucleoprotein or peptide (or protein). In some aspects, the specific example of the central nervous system disease or injury therapeutic agent can be, but is not limited to, N-methyl D-aspartate (NMDA) antagonists, chemotherapeutics, glutamate antagonists or immunomodulators (e.g., immunosuppressants or immune activators). In some aspects, gene therapy allows the delivery of genetic material encoding therapeutic molecules. In some aspects, gene therapy includes giving a subject a biopharmaceutical containing a recombinant nucleic acid to regulate, repair, replace, add or delete a gene sequence, thereby treating or curing a disease. In some aspects, nucleic acid can be a small RNA, such as, but not limited to, short interfering RNA (siRNA), microRNA (miRNA) and piwi-interacting RNA (piRNA). In certain aspects, the therapeutic agent can be an antibody targeting Aβ peptide / plaque (such as Donanemab, Lecanemab), Tau tangles, β-secretase, γ-secretase, acetylcholinesterase (AChE), butyrylcholinesterase (BuChE). In some aspects, nucleic acid therapy can be used to reduce the expression of Aβ peptide, Tau tangles, β-secretase, γ-secretase, acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), CD22.
[0161] In some aspects, the composition can be a composition comprising four MGS peptides coupled to two MTS peptides, wherein the four MGS peptides comprise the amino acid sequence GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1), EQRWVQMLHLQTRYAGEWPG (SEQ ID NO: 2), FQHNPFPYTYSMEDTDVEIK (SEQ ID NO: 3) or YAAWPASGAWT (SEQ ID NO: 4); wherein the two MTS peptides comprise the amino acid sequence DAYKLQTSLDWQMWNP (SEQ ID NO: 9), FPSWTSKNQQWTNQRQ (SEQ ID NO: 11) or SKETYSMNAQRQHERS (SEQ ID NO: 13).
[0162] As described in the full text, the composition may also include one or more joints. In some aspects, the disclosed composition may also include a first joint. In some aspects, the first joint is attached to the C-terminus of the MGS peptide. In some aspects, the first joint may be any joint described herein. In some aspects, the first joint may include a PEG joint, an alkyl joint, a maleimide joint, an amide joint, a peptide joint, an aryl joint, a dibenzocyclooctyne joint, an azide joint, a triazole joint, a bisbenzazacyclooctyne, 8,9-dihydro-1H-dibenzo [1,2,3] triazolo [4,45-d] azacyclooctyne or a combination thereof. In some aspects, the first joint may connect the MGS peptide to another MGS peptide, or connect the MGS polypeptide to a carrier, or connect the MGS peptide to another joint. In some aspects, the first joint may include one or more structures shown in Figure 3. For example, each MGS peptide may be attached to a joint, such as PEG (any length). The individual MGS peptide-PEGs can then be linked using one or more amino acids, modified amino acids, or linkers that can produce a dimer or tetramer core as described herein.
[0163] In some aspects, the composition may further include a second joint. In some aspects, the second joint is attached to the first joint. In some aspects, the second joint is also attached to the third joint. Thus, in some aspects, the composition may further include a third joint.
[0164] In some aspects, the third linker is attached to the second linker. In some aspects,
[0165] The third joint is attached to the C-terminus of the MTS peptide. In some aspects, the third joint can be any joint described herein. In some aspects, the third joint may include a PEG joint, an alkyl joint, a maleimide joint, an amide joint, a peptide joint, an aryl joint, a dibenzocyclooctyne joint, an azide joint, a triazole joint, a dibenzoazacyclooctyne, 8,9-dihydro-1H-dibenzo [1,2,3] triazolo [4,45-d] azacyclooctyne or a combination thereof. In some aspects, the third joint can connect the MTS peptide to another MTS peptide, or connect the MTS polypeptide to a carrier, or connect the MTS peptide to another joint. In some aspects, the third joint may include one or more structures shown in Figure 3. For example, each MTS peptide can be connected to a joint, such as PEG (any length). Then, one or more amino acids, modified amino acids, or joints that can produce dimers or tetramer cores described herein can be used to connect each MTS peptide-PEG.
[0166] In some aspects, the first joint and / or the second joint and / or the third joint include polyethylene glycol (PEG) joints, alkyl joints, maleimide joints, disulfide joints, peptide joints, amide joints, aryl joints, dibenzocyclooctyne joints, azide joints, triazole joints, bisbenzazacyclooctyne, 8,9-dihydro-1H-dibenzo [1,2,3] triazolo [4,45-d] azacyclooctene or a combination thereof. In some aspects, the first, second and / or third joints include PEG joints. In some aspects, PEG joints of any length can be used. For example, any PEG1-PEG30 can be used. In some aspects, the length of the joint is up to PEG5000.
[0167] In some aspects, the carrier is attached to the first joint, the second joint and / or the third joint. Thus, in some aspects, the disclosed compositions may include one or more carriers. In some aspects, one or more joints may include a carrier.
[0168] In some aspects, the MGS peptide, the MTS peptide, or both are protected at the N-terminus. For example, in some aspects, the MGS peptide, the MTS peptide, or both include N-terminal acetylation. Therefore, in some aspects, the MGS peptide or the MTS peptide can be any one of Table 1 and / or Table 2. H. Imaging Methods
[0169] Disclosed is a method for imaging the central nervous system of an object, comprising administering one or more compositions disclosed herein to an object in need thereof, wherein the carrier is an imaging agent. In some aspects, the imaging agent can be, but is not limited to, a dye, a radionuclide, a contrast agent, a fluorescent protein, or a fluorescent molecule. In some aspects, the imaging agent is attached to a protein, a peptide, or a nucleic acid.
[0170] In some aspects, the composition can be a composition comprising four MGS peptides coupled to two MTS peptides, wherein the four MGS peptides comprise the amino acid sequence GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1), EQRWVQMLHLQTRYAGEWPG (SEQ ID NO: 2), FQHNPFPYTYSMEDTDVEIK (SEQ ID NO: 3) or YAAWPASGAWT (SEQ ID NO: 4); wherein the two MTS peptides comprise the amino acid DAYKLQTSLDWQMWNP (SEQ ID NO: 9), FPSWTSKNQQWTNQRQ (SEQ ID NO: 11) or SKETYSMNAQRQHERS (SEQ ID NO: 13).
[0171] As described in the full text, the composition may also include one or more joints. In some aspects, the disclosed composition may also include a first joint. In some aspects, the first joint is attached to the C-terminus of the MGS peptide. In some aspects, the first joint may be any joint described herein. In some aspects, the first joint may include a PEG joint, an alkyl joint, a maleimide joint, an amide joint, a peptide joint, an aryl joint, a dibenzocyclooctyne joint, an azide joint, a triazole joint, a bisbenzazacyclooctyne, 8,9-dihydro-1H-dibenzo [1,2,3] triazolo [4,45-d] azacyclooctyne or a combination thereof. In some aspects, the first joint may connect the MGS peptide to another MGS peptide, or connect the MGS polypeptide to a carrier, or connect the MGS peptide to another joint. In some aspects, the first joint may include one or more structures shown in Figure 3. For example, each MGS peptide may be attached to a joint, such as PEG (any length). The individual MGS peptide-PEGs can then be linked using one or more amino acids, modified amino acids, or linkers that can produce a dimer or tetramer core as described herein.
[0172] In some aspects, the composition may further include a second joint. In some aspects, the second joint is attached to the first joint. In some aspects, the second joint is also attached to the third joint. Thus, the composition may further include a third joint.
[0173] In some aspects, the third joint is attached to the second joint. In some aspects, the third joint is attached to the C-terminus of the MTS peptide. In some aspects, the third joint can be any joint described herein. In some aspects, the third joint may include a PEG joint, an alkyl joint, a maleimide joint, an amide joint, a peptide joint, an amide joint, an aryl joint, a dibenzocyclooctyne joint, an azide joint, a triazole joint, a bisbenzazacyclooctyne, 8,9-dihydro-1H-dibenzo [1,2,3] triazolo [4,45-d] azacyclooctyne or a combination thereof. In some aspects, the third joint can connect the MTS peptide to another MTS peptide, or connect the MTS polypeptide to a carrier, or connect the MTS peptide to another joint. In some aspects, the third joint may include one or more structures shown in Figure 3. For example, each MTS peptide can be connected to a joint, such as PEG (any length). Then, each MTS peptide-PEG can be connected using an amino acid or a modified amino acid that can produce a dimer or tetramer core as described herein. For example, in some aspects, PEG can be added to deprotected lysine (ε-amino and amino terminus of the side chain) during Fmoc solid phase peptide synthesis. This can provide 2 free amino groups to couple PEG to form a dimer. For tetramers, a fully deprotected lysine can be coupled to another lysine in peptide synthesis. This can produce 4 free amino groups that can be used to attach PEG.
[0174] In some aspects, the first joint and / or the second joint and / or the third joint include polyethylene glycol (PEG) joints, alkyl joints, maleimide joints, disulfide joints, peptide joints, amide joints, aryl joints, dibenzocyclooctyne joints, azide joints, triazole joints, bisbenzazacyclooctyne, 8,9-dihydro-1H-dibenzo [1,2,3] triazolo [4,45-d] azacyclooctatetraene or a combination thereof. In some aspects, the first, second and / or third joints include PEG joints. In some aspects, PEG joints of any length can be used. For example, any PEG1-PEG30 can be used. In some aspects, the length that can be used is up to PEG5000.
[0175] In some aspects, the carrier is attached to the first joint, the second joint and / or the third joint. In some aspects, the disclosed composition may also include one or more carriers. In some aspects, one or more joints may include a carrier.
[0176] In some aspects, the MGS peptide, the MTS peptide, or both are protected at the N-terminus. In some aspects, the MGS peptide, the MTS peptide, or both include N-terminal acetylation. Therefore, in some aspects, the MGS peptide or the MTS peptide can be any one of Table 1 and / or Table 2. I. Dosage
[0177] Disclosed are dosing regimens comprising administering to a subject in need thereof a single dose of one or more disclosed compositions or peptides, wherein the single dose comprises an amount effective to enter the CNS and target a specific CNS cell type.
[0178] Disclosed is a dosing regimen comprising administering at least two doses of one or more disclosed compositions or peptides to a subject in need thereof, wherein the concentration of each dose is the same. In some aspects, each dose after the first dose can be reduced. In some aspects, each dose after the first dose can be increased.
[0179] In some aspects, a single dose can be continuous administration. In some aspects, continuous administration can be hours, days, weeks or months. In some aspects, there can be two or more doses. In some aspects, two or more doses can be given at intervals of several days, weeks or months. J. Kit
[0180] The above materials and other materials can be packaged together in any suitable combination as a kit for performing or assisting in the performance of the disclosed methods. It is useful if the kit components in a given kit are designed and suitable for use together in the disclosed methods. For example, a kit comprising one or more disclosed MGS peptides, MTS peptides, linkers and / or combinations thereof is disclosed. For example, a kit comprising any disclosed composition is disclosed. Example A. Example 1: Dual Targeting
[0181] Figure 5 Examples of structures of dimer cores with fatty acid modifications are shown. When CH3O-SKETYSMNAQRQHERS (SEQ ID NO: 14), the structure is called MTS3_V2-2. Similar structures can be prepared, wherein X is SEQ ID NO: 9 (MTS1) or SEQ ID NO: 10 (acetylated MTS1), SEQ ID NO: 11 (MTS2) or SEQ ID NO: 12 (acetylated MTS2).
[0182] Figure 6 A schematic diagram of the general experimental procedure used to evaluate the delivery of the disclosed compositions to the CNS is provided.
[0183] Lipidation of MTS3 with C16 fatty acids increased transport to CSF and brain (Figure 7). MTS variants labeled with the near-infrared dye AlexaFluor 750 were injected into the tail vein of Sprague-Dawley rats at 1 μg MTS / kg rat body weight. At the designated time, CSF was isolated by cisternal capillary puncture. Fig. 7A Concentrations of MTS3 variants isolated from CSF after the indicated in vivo circulation times are shown. MTS3_V2, which contains a C16 fatty acid modification, showed 2.2-7.6-fold higher CSF concentrations than non-lipidated MTS3_V1-2. To ensure that fatty acids do not drive transport into the CNS, a control peptide, scMTS3_V2-2, containing the amino acid composition of MTS3 but scrambled, was lipidated. Uptake of MTS3_V2-2 was 9-23-fold higher than scMTS3_V2-2, indicating that transport is dependent on the MTS3 sequence, rather than the fatty acid modification. Figure 7B The concentrations of the same MTS3 variants present in brain homogenate after the indicated circulation times are shown. Transport of MTS3_V2-2 to the brain parenchyma was 10-12-fold higher than non-modified MTS3_V1-2 and 17-31-fold higher than the scrambled control scMTS3_V2-2. Levels of MTS_V1-2 were below the limit of detection at 24 hours. Concentrations in brain tissue were higher than those in CSF, indicating diffusion throughout the brain and slower clearance.
[0184] Brain sectioning and fluorescence imaging revealed that brain accumulation of MTS3_V2-2 was enhanced compared with that of the parental MTS3_V1-2 ( Figure 8). Coronal sections are 1 mm and arranged from anterior (upper left) to posterior (lower right). Consistent with the data from brain homogenates, MTS3_V2-2 (C16 fatty acid modified) showed increased brain uptake at all time points compared to MTS3_V1-2. The fluorescent signal was distributed throughout the brain, indicating diffusion within the parenchyma.
[0185] Figure 3 shows an example of the core construct used for the microglia targeting experiments shown below. Figure 3A The dimer core is shown, Figure 3B The tetrameric core is shown. The core structure shown includes the MGS peptide indicated as X. The specific MGS peptide used in the following experiments was MGS2_V4, i.e. CH3CO-YAAWPASGAWT. Specifically, the tetrameric core MGS2_V4-4 was used.
[0186] MGS2_V4-2 was specific for microglia and promoted high levels of cellular uptake ( FIG. 9 ). Fig.9A showed that MGS2_V4-2 binds with high affinity and is internalized into microglia, Fig. 9B MGS2-V4-2 was shown to bind and internalize into resting and activated microglia. Compared with neurons, Schwann cells, and astrocytes, MGS2_V4-2 was specific for microglia ( Fig. 9C ).
[0187] Fig.10 The optimized MGS2_V4-2 is shown to be stable in human serum. MGS2_V4-2 labeled with AlexFluor 647 was incubated in human serum at 37°C. At the indicated times, aliquots were removed, serum proteins were precipitated, and the resulting supernatant was analyzed by reverse phase HPLC monitoring absorbance at 650 nm. Chromatograms at various time points are shown. The retention time of the intact peptide is 11.864. A new substance with a retention time of 10.005 minutes was observed at 1 hour and continued to increase over time. The peaks were integrated to determine the percentage of intact peptide as well as the amount of degradation products observed. At 24 hours, >75% of MGS2_V4-2 was still intact. The peptide product that appeared at a retention time of 10.005 minutes was analyzed by electrospray mass spectrometry. The mass of this new substance corresponds to the loss of 3 amino acids on both branches of MGS2_V4-2.
[0188] Fig.12 The general concept of dual targeting of specific cell types in the CNS is shown. Fig.12The figure shows an example of MGS2_V4-2, MTS3_V12-MGS2_V4-2 chimera and MTS3_V1-2 uptake measured on HMC3 cells. Cells were incubated at the specified concentrations of each peptide construct labeled with Alexa Fluor 647. After incubation for 1 hour at 37°C, uptake was determined by quantitative flow cytometry. MGS2_V4-2 and MTS3_V12-MGS2_V4-2 chimeras showed the same EC50 and cellular uptake, indicating that the attachment of MTS3_V1-2 did not affect the cellular efficacy of MGS2_V4-2. As expected, MTS3_V1-2 did not show significant cellular uptake at any tested concentration. Therefore, uptake is mediated by MGS rather than MTS.
[0189] Figure 13 shows dual targeted internalization of MTS-MGS chimeras into microglia observed by confocal microscopy. HMC3 cells were incubated with 25nM of MTS3_V12-MGS2_V4-2 conjugate labeled with Alexa Fluor 647. After 1 hour, the peptide solution was removed. Cell membranes were labeled with wheat germ agglutinin coupled to Alexa Fluor 488 and cell nuclei were stained with Hoechst 33342. Live cell imaging was performed on a Zeiss LSM 700. Representative single z-slice images are shown. Cells treated with Alexa Fluor 647 dye alone ( Fig.13A ) or a chimeric construct made with the scrambled form of the MGS2 peptide, SAWAGAYPWAT (SEQ ID NO: 17) ( Fig. 13B ) did not show AlexaFluor 649 staining, indicating cellular uptake. In contrast, internalization of MTS3_V1-2-MGS2_V4-2 into HMC3 cells was confirmed by spot staining around the cells ( Fig. 13C This indicates that MGS2_V4-2 mediates cellular internalization into HMC3 cells and is consistent with flow cytometric analysis of quantitative uptake.
[0190] Figure 14 shows that dual targeting of the MTS3_V1-2-MGS2_V4-2 chimera targets microglia in the central nervous system. Staining was observed only in microglia. No microglia staining was observed with the conjugates using MTS alone, MGS alone, or a scrambled control form.
[0191] Fig.15It is shown that the dual targeting of MTS3_V1-2-MGS2_V4-2 chimera is confirmed by flow cytometry to target microglia in the central nervous system. The MTS3_V1-2-MGS2_V4-2 conjugate is labeled with Alexa Fluor 647 (red) and injected into the lateral tail vein of Sprague Dawley rats at a dose of 0.09nmol / g. After 2 hours of circulation time, the animals are euthanized and brain tissue is harvested. The brain is separated using a Miltenyi Biotec gentleMACS Octo dissociator. Whole brain cells are incubated with CD11b / c (microglia) magnetic microbeads (Miltenyi Biotec) and separated from other parts of the brain by a Miltenyi QuadroMACS separator. Microglia are subsequently stained with Iba1 microglia markers. Flow cytometry data are collected by BD FACSCelesta. Animals treated with the MTS3_V1-2-MGS2_V4-2 conjugate showed a positive shift in microglia (IBA1-positive) but not in other CNS cells (IBA1-negative; Fig.15 ).
[0192] Fig.16 The structure of the MTS3_V1-2-MGS2_V4-4 chimera used for the siRNA delivery experiments shown in Figure 18 is shown. Fig.17 A similar structure was used for the other linked MTS3_V1-2-MGS2_V4-4 chimeras.
[0193] FIG. 18 shows an example of siRNA delivery with MGS2-MTS3 chimeras in microglial cells. Fig.18AThe structure of chimera MGS2_V4-4 (tetramer)-MTS3_V1-2 is shown, which is coupled to test siRNA by click chemistry. Surprisingly, the combination of siRNA and MGS2_V4-2 (dimer)-MTS3_V1-2 causes the loss of combination with HMC3 cells. However, by using tetramer MGS2_V4-4 as the targeting peptide in this multifunctional chimera, the combination (as shown in Figure A) is saved. Figure B shows the uptake of MGS2_V4-4-MTS3_V1-2 and MGS2_V4-4-MTS3_V1-2-siRNA. There is no significant difference in the EC50 uptake entering HMC3 cells, indicating that the combination of siRNA will not destroy the ability of the chimera to be internalized in microglia. Furthermore, MGS2_V4-4-MTS3_V1-2 showed better affinity and higher uptake than the dimeric MGS2_V4-2-MTS3_V1-2, indicating that MGS2_V4-4 is superior to MGS2_V4-2 in targeting microglia in this context. Unexpectedly, siRNA coupled to the MGS2_V4-2 (dimer)-MTS3_V1-2 chimera significantly reduced uptake in microglia, however, using the tetrameric MGS2_V4-4 overcame this problem
[0194] Fig.19 The results for demonstrating neuronal cell targeting are shown Figure 20-2 Structure of the tetrameric MGS_NOE3_V2-4 core.
[0195] Fig. 20 The structure of the MGS_NOE3_V2 peptide sequence is shown. The sequence is CH3-CO-GFHNVYTWGGFSDIDLDMADEI. The MGS_NOE3_V1 peptide sequence is identical but does not contain the N-terminal protecting group. Therefore, Fig. 20 The structure replaces Fig.19 X in the structure of .
[0196] Figure 21 shows that the tetrameric MGS_NOE3_V2-4 is specific for neural cells and promotes high levels of cellular uptake. Monomeric and dimeric MGS_NOE3_V2 do not bind. It must be on the tetrameric core to function. Fig.21AShown is the uptake of MGS_NOE3_V1-4 and MGS_NOE3_V2-4 incubated with the specified cell lines for 1 hour at 200nM. The number of peptide molecules internalized by each cell was determined by quantitative flow cytometry. The uptake in two neuronal cell lines HT22 (mouse hippocampal neuronal cell line) and GT1 / 7 (mouse hypothalamic neuronal line) was significantly higher than that of CTX TNA2 (rat astrocytes from the frontal cortex), HMC3 (human microglial cell line), H1299 and H460 (both human non-small cell lung cancer cell lines). The specificity of MGS_NOE3_V1-4 and MGS_NOE3_V2-4 for neurons is 5-6 times that of astrocytes, and 3 times that of microglial cells. Fig.21B The uptake of MGS_NOE3_V2-4 into HT22 cells was shown to increase with increasing concentrations. The uptake of the monomeric (MGS_NOE3_V2-1) and dimeric (MGS_NOE3_V2-2) forms was also assessed by incubation at 37°C for 1 h, and no uptake was observed on HT22 cells, indicating that MGS_NOE_V2 must be located on the tetrameric core to induce binding and uptake into neurons. Fig. 21C The uptake of MGS_NOE3_V2-4 is shown to increase over time. HT22 cells were incubated with 200 nM MGS_NOE3_V2-4 at 37°C for the indicated time points. Uptake was determined by flow cytometry.
[0197] Recycling of cell receptors of MGS_NOE3_V2-4 ( Fig. 22 ). HT-22 cells were incubated with medium containing 100 nM MGS_NOE3_V2-4 in the presence of 100 μM chloroquine or 250 μM cycloheximide for the indicated times. Cellular uptake was analyzed by flow cytometry. Cycloheximide, which inhibits new protein synthesis, had no effect on the uptake of MGS_NOE3_V2-4, indicating that new protein synthesis is not required for sustained uptake. However, chloroquine, an inhibitor of endosomal acidification and trafficking, greatly reduced uptake starting at 1 h of incubation and continued to inhibit internalization of MGS out to 24 h. Sustained uptake of MGS_NOE3_V2-4 does not require new protein synthesis. Sustained uptake of MGS_NOE3_V2-4 requires endosomal acidification. MGS_NOE3_V2-4 uptake persists over time. Collectively, these data suggest that MGS_NOE3_V2-4 is internalized by its cellular receptor and then recycled back to the cell surface, where it can repeatedly internalize more MGS_NOE3_V2-4.
[0198] MGS_NOE3_V2-4 is internalized into neuronal cells (Figure 23). HT22 cells were incubated with 200nM of MGS_NOE3_V2-4-streptavidin-AlexaFluor 647 conjugate at 37°C for the indicated time. AlexaFluor488-coupled wheat germ agglutinin was used to label the cell membrane, and Hoechst33342 was used to stain the nucleus. Live cell imaging was performed, and representative images are shown. Red spot staining was observed in the cells at 4 hours ( Fig. 23B ), and continues to increase over time ( Fig.23C ). Panel A shows a control sample containing streptavidin 647 but without MGS_NOE3_V2-4. The lack of red staining indicates that MGS_NOE3_V2-4 mediates cellular uptake. The red staining located at the cell periphery (green staining) indicates cellular internalization of MGS_NOE3_V2-4.
[0199] Figures 24A-24C MGS_NOE3_V2-4 is shown to associate with cells in the central nervous system after intrathecal injection. MGS_NOE3-V2-4 was labeled with Alexa Fluor 647 and injected intrathecally into C57BL / 6 mice. After the peptide circulated for 1 hour, the animals were killed and the brain tissue was harvested. The whole brain was then isolated using a Miltenyi Biotec gentleMACS Octo dissociator. The number of MGS_NOE3_V2-4 molecules internalized into brain cells was analyzed by flow cytometry (BD FACSCelesta).
[0200] Fig.25 shows the use of Figure 26 and Fig. 27 MTS3_V1-2-MGS_NOE3_V2-4 chimera for the indicated experiments.
[0201] Figures 26A-26C The internalization of the MTS3_V1-2-MGS_NOE3_V2-4 chimera into HT22 neuronal cells is shown. Punctate staining in the cells was observed at 1 hour and continued to increase over time. Fig.26A A control sample containing AlexaFluor 647 but without MGS_NOE3_V2-4 is shown, as well as HT22 cells alone. Internalization of the dual-target chimera MTS3_V1-2-MGS_NOE3_V2-4 into HT22 cells was observed by staining within the cell membrane boundary ( Fig.26C). Uptake of the dual-target chimera MTS3_V12--MGS_NOE3_V2-4 was reduced 3-fold compared to MGS_NOE3_V2-4 alone, but was still significant. Uptake of the dual-target chimera MTS3_V1-2-MGS_NOE3_V2-4 continued over time, reaching nearly 250,000 molecules / cell (≈250 nM) at 24 h. Taken together, these data suggest that the MTS3_V1-2-MGS_NOE3_V2-4 chimera retains the ability to internalize into neuronal cells, reaching intracellular levels of approximately 250 nM at 24 h, and that this uptake is driven by the MGS_NOE3_V2-4 component of the chimera.
[0202] Fig. 27 MTS2_V1-2 is shown to bind to the transferrin receptor to enter the central nervous system, while MTS3_V1-2 utilizes a novel cellular receptor that has not yet been identified for transport. Recombinant human transferrin receptor was absorbed by a high binding ELISA plate at a concentration of 1 μg / mL. Biotinylated MTS2_V1-2 or MTS3_V1-2 was incubated for 1 hour at different concentrations, and then the samples were recovered and the plates were washed to remove excess peptides. The retained MTS peptides were detected using streptavidin-HRP and TMB reagents. The absorbance was measured at 450nm and was proportional to the amount of MTS peptide captured by the transferrin receptor. As shown in the figure, MTS2_V1-2 binds to human transferrin in a concentration-dependent manner and is saturated at higher concentrations. In contrast, scrambled control peptides of MTS3_V1-2 and MTS2_V1-2 showed no binding. The binding affinity of MTS2_V1-2 to the transferrin receptor was determined by biolayer interferometry on the OctetRED 96 system. The biotinylated MTS2_V1-2 peptide was captured by a streptavidin probe. The kon and koff rates were measured at different concentrations of human or mouse transferrin receptor, thereby determining the dissociation constant. The Kd for MTS2_V1-2 binding to the transferrin receptor was 210 nM for the human protein and 12 nM for the mouse receptor. Taken together, these data support that the transferrin receptor is the target of MTS2_V1-2. The receptor for MTS3_V1-2 remains unknown, but the data suggest that it is not the transferrin receptor and that this peptide may enter the CNS via a different mechanism than MTS2_V1-2. 1. Materials and Methods General method for quantification of peptide internalization in i cells.
[0203] Cells were incubated with the desired peptide (MGS, MTS or MGS-MTS conjugate) labeled with Alexa Fluor 647 in complete medium at 37°C. The peptide concentration and incubation time as well as the cell line used are indicated in each figure. The peptide was removed and the cells were washed 3 times with PBS (137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4, pH 7.4), washed 2 times with 0.1M HCl-glycine pH 2.2 in 0.9% NaCl, and rinsed once with PBS. The cells were removed by trypsin digestion. Flow cytometry was performed on a BD FACSCelesta, and the data were analyzed using FlowJo_v10.8. Cells were gated based on forward and side scatter to include only live cells, and at least 10,000 events were counted. For the absolute peptide uptake of each cell, Quantum TM Alexa Fluor 647 microspheres were used to generate a standard curve. MFI was measured at 50% of peak height. The number of molecules internalized by each cell was determined from the standard curve of MESF vs. MFI and divided by the number of dye molecules / MGS conjugate. GraphPad Used for nonlinear regression curve fitting to calculate EC50.
[0204] To determine whether cellular receptors were recycled, cells were treated with peptides in the presence of 100 μM chloroquine or 250 μM cycloheximide. At the indicated time points, cells were washed and analyzed as above. ii. CNS cell lines for uptake studies
[0205] All cell lines were maintained according to the manufacturers' protocols and media supplies. Cell lines Cell Type supplier HT22 Mouse hippocampal neurons Sigma-Aldrich GT1 / 7 Mouse hypothalamic GnRH neurons Sigma-Aldrich HMC3 Human microglial cells ATCC CTX TNA2 Rat astrocyte type 1 ATCC RN33B Rat neuronal Schwann cells ATCC HMC3 cells were activated with interferon-γ (IFN-γ) (10 ng / ml, 24 hours). The quiescent phenotype was characterized by the expression of IBA1 and the endotoxin receptor CD14, but was negative for the astrocyte marker GFAP. Markers of activated microglia, namely MHCII, CD68 and CD11b were negative in quiescent HMC3 cells but upregulated upon activation. iii. In vivo MTS and MTS-MGS targeting experiments
[0206] MTS peptides directly coupled to Alexa Fluor 750 dye (1 μg / g body weight) were injected into Sprague-Dawley rats via the lateral tail vein and allowed to circulate for designated times (20 minutes, 1 hour, 6 hours, 24 hours). Animals were anesthetized 10 minutes before the end of the time point and injected intraperitoneally with 2mL 200x heparinized saline. In order to collect CSF, blunt dissection was performed on the back of the neck to expose the transparent dura covering the brain medullary pool. Using a glass micropipette, CSF was aspirated from the brain medullary pool at designated time points. After collecting CSF, transcardial perfusion was performed by flushing with 500mL of ice-cold 1x PBS containing heparin to remove any blood from the body. Separate the brain and other tissues. Use a Dounce homogenizer to homogenize the brain in lysis buffer (30mM Tris-HCl, pH 8.00.05% Triton X-100) and collect the soluble portion. A standard curve using MTS peptide coupled to AlexaFluor 750 was generated to determine the amount of dye in CSF and brain.
[0207] If the brain is to be used for tissue sectioning, it is first perfused and then perfused with 500 mL of ice-cold 5% paraformaldehyde. 1 mm thick coronal sections are prepared using the brain matrix. The sections are imaged on an Odyssey Imager, collecting fluorescent signals at 800 nm. iv. Confocal microscopy analysis of in vitro cells
[0208] 24 hours before treatment, test cells were seeded in 35 mm confocal microscopy dishes. Test peptides labeled with Alexa Fluor 647 were incubated in cells for the indicated time in culture medium at 37°C. After incubation, cells were washed 3 times with PBS, 2 times with 0.1 M HCl-glycine pH 2.2 in 0.9% NaCl, and 1 time with PBS. Cell membranes were labeled with wheat germ agglutinin conjugated with Alexa Fluor 488, and cell nuclei were stained with Hoechst 33342. Microscopy was performed on a Zeiss LSM 700 using a Pln Apo 63x / 1.4 oil DIC III objective. Images were processed using Zen software.
[0209] For peptides that were biotinylated rather than directly labeled with Alexa Fluor 647, AlexaFluor 647 was added to the TMThe peptide-SA-AF647 conjugate was prepared by mixing the streptavidin and biotinylated peptide in an equal molecular ratio in 100 μl PBS for 30 minutes. After coupling, 900 μl of culture medium containing biotin (600 nM) was added to the mixture to saturate all binding sites on the streptavidin. The cell culture medium was then replaced with the peptide-containing mixture. The final peptide-SA-AF647 is shown in each figure. Microscopic examination was performed as described above. v. Confocal microscopy and flow cytometric analysis of in vivo delivery experiments.
[0210] As described above, MTS, MGS or MTS-MGS labeled with Alexa Fluor 647 were injected into Sprague-Dawley rats. After a circulation time of 2 hours, the animals were sacrificed and the brains were fixed by transcardial perfusion, collected and cryoprotected, and cryosectioned into 15 μm sections on a Leica CM1950. Images were taken using a Zeiss LSM 800. Microglia were stained with Iba-1 and nuclei were stained with Hoechst 33342.
[0211] For flow cytometry analysis, brains were isolated using a Miltenyi Biotec gentleMaCS Octo dissociator. Whole brain cells were incubated with CD11b / c (microglia) magnetic microbeads (Miltenyi Biotec) and separated from the rest of the brain using a Miltenyi QuadroMACS separator. Microglia were subsequently stained with the Iba1 microglial marker. Flow cytometry data were collected using a BD FACSCelesta.
[0212] Alternatively, all CNS cells were analyzed as a mixture by dissociating the brain using a Miltenyi BiotecgentleMACS Octo dissociator. No enrichment for CNS subpopulations was performed and cells were analyzed directly by flow cytometry. Gating was used to eliminate cell debris and cell doublets. vi. Serum stability
[0213] The concentration of the peptide solution coupled to the dye (Alexa Fluor 647) was measured by the absorbance at 651nm, and about 14nmol of the peptide was lyophilized. The lyophilized peptide powder was dissolved in 400μL human serum (Innovative Research, H6430) to obtain a 35μM solution. The samples were incubated with shaking at 37°C. For each time point (0, 1, 2, 4, 20 and 24 hours), 50μL aliquots were taken out from the reaction and 100μL of anhydrous ethanol was added to precipitate serum proteins. The samples were incubated on ice for 15 minutes and then centrifuged at 12000rpm for 5 minutes. Subsequently, 50μL supernatants were recovered and diluted in 150μL PBS. Finally, each sample of 100μL was analyzed by analytical RP-HPLC. B. Example 2: Reaction Scheme
[0214] Figures 28-32 show examples of different reaction schemes for preparing the disclosed peptides and compositions.
[0215] Preparation of resin for dimer core: To synthesize 25 μmole of peptide (MGS2_V4-2), 80 mg of RinkAmide MBHA resin (Gyros Protein Technology, capacity 0.31 mmol / g) was weighed into a 45 mL reaction vessel and transferred to a peptide synthesizer (PurePep Chorus, Gyros Protein Technology) for automated synthesis. The resin was swollen in 6 mL of a 1:1 N,N-dimethylformamide (DMF, Fisher) / dichloromethane (DCM, Fisher) mixture for 30 minutes and then drained.
[0216] Preparation of resin for tetramer core: To synthesize 12.5 μmole of peptide (MGS2_V4-4), 40 mg of Rink Amide MBHA resin (Gyros Protein Technology, capacity 0.31 mmol / g) was weighed into a 45 mL reaction vessel and transferred to a peptide synthesizer (PurePep Chorus, Gyros Protein Technology) for automated synthesis. The resin was swollen in 6 mL of a mixture of 1:1 N,N-dimethylformamide (DMF, Fisher) / dichloromethane (DCM, Fisher) for 30 minutes and then drained.
[0217] Manual addition of modified amino acids: Manual coupling mixture (relative to resin), which usually contains 4.4 equivalents of HCTU (Gyros Protein Technology), 10 equivalents of N-methylmorpholine (NMM, Gyros Protein Technology), 5 equivalents of Oxyma pure (Gyros Protein Technology) and 5 equivalents of modified amino acids. These include, but are not limited to, Fmoc-S-tert-butylthio-L-cysteine (CHEM-IMPEX INT'L INC), Nα-Fmoc-Nε-azido-L-lysine (CHEM-MPEX INT'L INC) and Fmoc-Lys (palmitoyl Glu-OtBu) -OH (BACHEM) dissolved in 1 mL of DMF. After coupling for 1 hour, the peptide resin was washed, including two 3 mL DMF washes, two 3 ml DCM washes and three 3 ml DMF washes, mixing for 20 seconds each time.
[0218] Manual addition of linker: A manual coupling mixture containing 16 equivalents of N,N′-diisopropylcarbodiimide (DICGyros Protein Technology), 16 equivalents of N-methylmorpholine (NMM, Gyros Proteins Technology), 8 equivalents of Fmoc-amino-PEG-propionic acid (Polypure) and 8 equivalents of Oxyma pure (Gyros ProteinTechnology) was dissolved in 1 mL of DMF. After 2 hours of coupling, the peptide resin was washed again (as described above).
[0219] Manual addition of maleimide-propionic acid: A manual coupling mixture containing 16 equivalents of N,N′-diisopropyl-carbodiimide (DIC Gyros Protein Technology), 16 equivalents of N-methylmorpholine (NMM, Gyros Proteins Technology), 8 equivalents of 3-maleimide-propionic acid (Polypure) and 8 equivalents of Oxyma pure (Gyros Protein Technology) was dissolved in 1 mL of DMF. After 2 hours of coupling, the peptide resin was washed again (as described above).
[0220] Automated peptide synthesis: Peptides (MGS2_V4-2 and MGS2_V4-4) were synthesized on PurePep Chorus using Fmoc solid phase peptide synthesis. Deprotection and coupling steps were mixed using nitrogen bubbles. All steps were performed at room temperature.
[0221] Deprotection Deprotection consisted of two consecutive treatments (5 and 10 min) with 2 mL of 20% piperidine (Sigma-Aldrich) in a 0.1 M Oxyma pure (Gyros Protein Technology) / DMF solution. Deprotection was followed by washing (as described above).
[0222] Coupling The coupling step included 1 mL 0.25M Fmoc-amino acid (Gyros Protein Technology) in a 0.25M Oxyma pure / DMF solution, 0.5 mL 0.44M HCTU (Gyros Protein Technology) in DMF, and 0.5 mL 1M N-methylmorpholine (NMM, Gyros Protein Technology) in DMF. After continuous coupling for 30 minutes and 1 hour, the peptide resin was washed again (as described above). After all coupling steps were completed, the peptide resin was deprotected and washed to prepare for N-terminal amine acetylation.
[0223] Acetylation: Acetylation of the N-terminal amine included two 20-minute treatments with a 2 mL solution of 0.2 mL acetic anhydride (Fisher), 0.2 mL NMM, and 1.6 mL DMF. Acetylation was followed by 4 washes with 3 mL DMF and 8 washes with 3 mL DCM. The peptide resin was then dried in vacuo on a Prelude for 1 hour.
[0224] Cleavage / cleavage: The peptide resin was transferred to a 5 mL filter syringe and cleaved with 5 mL of a cleavage mixture consisting of 92.5% trifluoroacetic acid (TFA, Fisher), 5% triisopropylsilane (Sigma-Aldrich), and 2.5% MQ water. The cleavage mixture was stirred for 2-3 hours and immersed in cold ether (Fisher) and shaken vigorously to precipitate the peptide. The mixture was centrifuged at 2000 rpm for 2 minutes at room temperature and the supernatant was decanted. The crude peptide pellet was washed twice with fresh ether, dried in a fume hood, and dried overnight in a vacuum desiccator.
[0225] Crude peptide preparation and purification on RP-HPLC: The crude peptide was weighed and dissolved in a solution of 20-40% acetonitrile (Fisher), 80-60% MQ water and 0.1% TFA. The peptide solution was vortexed, sonicated and stirred for about 1 hour. After dissolution, the peptide solution was filtered through a 0.2 mm filter syringe in preparation for RP-HPLC and analysis. Peptide purification was performed using a Waters Prep LC 2767 system with MQ water containing 0.1% TFA (buffer A) and acetonitrile containing 0.1% TFA (buffer B) as mobile phases. Each injection was performed through a Phenomenex Jupiter 5mm C4 Column (200x212mm) was carried out at a flow rate of 10mL / min, using a gradient of 20-70% buffer B (0-3 minutes 20%, 3-25 minutes 20-70%, 25-30 minutes 90%, 30-35 minutes 20%), and operated at room temperature. The collected fractions were evaluated for purity by analytical RP-HPLC and ESI-MS and lyophilized.
[0226] Coupling between maleimide core and peptide (MGS or MTS): The lyophilized maleimide core was weighed and dissolved in 3M GuHCl / PBS. Subsequently, the lyophilized MGS / MTS peptides were dissolved separately in 3M GuHCL / PBS, and the pH of the solution was measured and adjusted to about 7 (if necessary). The solutions were combined to produce a 1.0:2.2 molar equivalent of maleimide-core to peptide. The reaction was stirred for about 3 hours and then purified on a preparative RP-HPLC (Agilent 1260). The peptide product was collected, characterized by analytical RP-HPLC and ESI-MS, and then lyophilized ( Fig.29 ).
[0227] Addition of DBCO: The lyophilized peptide was dissolved in a 3M guanidine chloride (GuHCl, Sigma-Aldrich) PBS solution. The pH of the solution was measured and adjusted to about 6.8 (if necessary). Subsequently, 1.2 equivalents of maleimide-PEG4-DBCO (Sigma-Aldrich) were added to the peptide solution, which was also dissolved in a 3M GuHCl / PBS solution. The reaction was stirred for about 30 minutes and then purified on a preparative RP-HPLC (Agilent 1260). The peptide product was collected, characterized by analytical RP-HPLC and ESI-MS, and then lyophilized ( Fig.30 ).
[0228] Chimeric peptide synthesis: The lyophilized peptide (MGS or MTS) with DBC attached and the lyophilized peptide (MGS or MTS) with Nα-Fmoc-Nε-azido-L-lysine incorporated in its core were weighed and dissolved separately in 3M GuHCl / PBS. The pH of each solution was determined and adjusted to about 7 (if necessary). The solutions were combined to produce a 1:1.2 molar equivalent of the peptide attached to DBCO to the peptide with Nα-Fmoc-Nε-azido-L-lysine. The reaction was stirred overnight and then purified on a preparative RP-HPLC (Agilent 1260). The peptide products were collected, characterized by analytical RP-HPLC and ESI-MS, and then lyophilized ( Fig.31 ).
[0229] Coupling of siRNA to chimeric peptide: The chimeric peptide containing free DBCO (composed of any core structure) is dissolved in nuclease-free PBS (NF-PBS), and its pH is measured and adjusted to about 7 (if necessary). Subsequently, siRNA with azide incorporated at the 5' or 3' end is dissolved in NF-PBS and its concentration is determined by measuring the absorbance at 260 nm. The solutions are combined to produce a 1:1.2 molar equivalent of siRNA to peptide. The reaction is stirred for about 3-7 days and then purified on analytical grade RP-HPLC (Agilent1220). The fractions are collected, combined, and characterized by analytical grade RP-HPLC and then lyophilized ( Fig.32 ).
[0230] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments of the methods and compositions described herein. Such equivalents are intended to be encompassed by the appended claims.
Claims
1. A peptide comprising the following amino acid sequence: GFHNVYPYTWGGFSDIDLMADEI(SEQ ID NO:1); EQRWVQMLHLQTRYAGEWPG(SEQ ID NO:2); or FQHNPFPYTYSMEDTDVEIK (SEQ ID NO: 3).
2. The peptide of claim 1, wherein the peptide has an N-terminal protecting group.
3. The peptide of claim 2, wherein the N-terminal protecting group is an acetyl group.
4. The peptide according to any one of claims 1 to 3, wherein The peptide further comprises a linker.
5. The peptide of claim 4, wherein the linker comprises a polyethylene glycol (PEG) linker, an alkyl linker, a maleimide linker, a peptide linker, an amide linker, an aryl linker, a dibenzocyclooctyne linker, an azide linker, a triazole linker, a bisbenzazacyclooctyne, 8,9-dihydro-1H-dibenzo[1,2,3]triazolo[4,45-d]azacyclooctatetraene, or a combination thereof.
6. The peptide of claim 5, wherein the PEG linker is PEG12 or PEG14.
7. The peptide of any one of claims 4-6, wherein the linker is attached to the C-terminus of the peptide.
8. A composition comprising at least one molecular guide sequence (MGS) peptide coupled to at least one molecular transport sequence (MTS) peptide, wherein the MGS peptide comprises the following amino acid sequence: GFHNVYPYTWGGFSDIDLMADEI(SEQ ID NO:1); EQRWVQMLHLQTRYAGEWPG(SEQ ID NO:2); FQHNPFPYTYSMEDTDVEIK(SEQ ID NO:3); or YAAWPASGAWT (SEQ ID NO: 4).
9. A composition comprising two or more molecular guide sequence (MGS) peptides coupled to two or more molecular transport sequence (MTS) peptides, wherein the two or more MGS peptides comprise the following amino acid sequence: GFHNVYPYTWGGFSDIDLMADEI(SEQ ID NO:1); EQRWVQMLHLQTRYAGEWPG(SEQ ID NO:2); FQHNPFPYTYSMEDTDVEIK(SEQ ID NO:3); or YAAWPASGAWT (SEQ ID NO: 4).
10. The composition of claim 9, wherein the two or more MGS peptides are four MGS peptides.
11. The composition of any one of claims 9-10, wherein the two or more MGS peptides are the same MGS peptide.
12. The composition of any one of claims 9-11, wherein the two or more MTS peptides are the same MTS peptide.
13. The composition of any one of claims 8-12, wherein the MGS peptide has an N-terminal protecting group.
14. The peptide of claim 13, wherein the N-terminal protecting group is an acetyl group.
15. The composition of any one of claims 8-14, further comprising a first linker.
16. The composition of claim 15, wherein the first linker is attached to the C-terminus of the MGS peptide.
17. The composition of any one of claims 15-16, further comprising a second linker.
18. The composition of claim 17, wherein the second linker is attached to the first linker.
19. The composition of any one of claims 17-18, further comprising a third linker.
20. The composition of claim 19, wherein the third linker is attached to the second linker.
21. The peptide of any one of claims 17-20, wherein the third linker is attached to the C-terminus of the MTS peptide.
22. The composition of any one of claims 15-21, wherein the first linker and / or the second linker and / or the third linker comprises a polyethylene glycol (PEG) linker, an alkyl linker, a maleimide linker, a disulfide linker, a peptide linker, an amide linker, an aryl linker, a dibenzocyclooctyne linker, an azide linker, a triazole linker, a bisbenzazacyclooctyne, 8,9-dihydro-1H-dibenzo[1,2,3]triazolo[4,45-d]azacyclooctatetraene, or a combination thereof.
23. The composition of claim 22, wherein the linker comprises a PEG linker.
24. The composition of any one of claims 8-23, further comprising a carrier.
25. The composition of claim 24, wherein the cargo is attached to the first linker, the second linker and / or the third linker.
26. The composition of any one of claims 24-25, wherein the cargo is a nucleic acid sequence, a peptide, a protein or a small molecule.
27. The composition of any one of claims 24-26, wherein the cargo is an imaging agent, an antibody and / or siRNA.
28. The composition of any one of claims 8-27, wherein the MTS peptide is targeted to the central nervous system.
29. The composition of any one of claims 8-28, wherein the MTS peptide comprises the following amino acid sequence: DAYKLQTSLDWQMWNP(SEQ ID NO:9); FPSWTSKNQQWTNQRQ(SEQ ID NO:11); or SKETYSMNAQRQHERS (SEQ ID NO:13).
30. The composition of any one of claims 8-29, wherein the MTS peptide comprises an N-terminal protecting group.
31. The peptide of claim 30, wherein the N-terminal protecting group is an acetyl group.
32. A composition comprising four molecular guide sequence (MGS) peptides coupled to two molecular transport sequence (MTS) peptides, The four MGS peptides comprise the following amino acid sequences: GFHNVYPYTWGGFSDIDLMADEI(SEQ ID NO:1); EQRWVQMLHLQTRYAGEWPG(SEQ ID NO:2); FQHNPFPYTYSMEDTDVEIK(SEQ ID NO:3); or YAAWPASGAWT (SEQ ID NO: 4); The two MTS peptides comprise the following amino acid sequences: DAYKLQTSLDWQMWNP(SEQ ID NO:9); FPSWTSKNQQWTNQRQ(SEQ ID NO:11); or SKETYSMNAQRQHERS (SEQ ID NO:13).
33. The composition of claim 32, wherein the four MGS peptides are the same or different MGS peptides.
34. The composition of any one of claims 32-33, wherein the two MTS peptides are the same or different MTS peptides.
35. The composition of any one of claims 32-34, wherein the MGS peptide has an N-terminal protecting group.
36. The peptide of claim 35, wherein the N-terminal protecting group is an acetyl group.
37. The composition of any one of claims 32-36, further comprising a first linker.
38. The composition of claim 37, wherein the first linker is attached to the C-terminus of at least one MGS peptide.
39. The composition of any one of claims 37-38, further comprising a second linker.
40. The composition of claim 39, wherein the second linker is attached to the first linker.
41. The composition of any one of claims 39-40, further comprising a third linker.
42. The composition of claim 41, wherein the third linker is attached to the second linker.
43. The peptide of any one of claims 41-42, wherein the third linker is attached to the C-terminus of the at least one MTS peptide.
44. The composition of any one of claims 37-43, wherein the first linker and / or the second linker comprises a polyethylene glycol (PEG) linker.
45. The composition of claim 44, wherein the PEG linker is PEG12 or PEG24.
46. The composition of any one of claims 32-45, further comprising a carrier.
47. The composition of claim 46, wherein the cargo is attached to the first linker, the second linker and / or the third linker.
48. A composition as described in any of claims 46-47, wherein the cargo is a nucleic acid sequence, a peptide, a protein or a small molecule.
49. The composition of claim 48, wherein the cargo is an imaging agent, an antibody or a siRNA.
50. The composition of any one of claims 32-49, wherein the MTS peptide is targeted to the central nervous system.
51. The composition of any one of claims 32-50, wherein the MTS peptide comprises an N-terminal protecting group.
52. The peptide of claim 51, wherein the N-terminal protecting group is an acetyl group.
53. A method of delivering a cargo to the CNS of a subject, comprising administering one or more compositions of claims 24-31 to a subject in need thereof, wherein a peptide coupled to the cargo enters the CNS.
54. The method of claim 53, wherein the composition enters the choroid plexus.
55. The method of any one of claims 53-54, wherein the composition enters the cerebrospinal fluid (CSF).
56. The method of claim 55, wherein the CSF transports the composition throughout the CNS.
57. The method of any one of claims 53-56, wherein the MGS targets the cargo to specific CNS cells.
58. The method of claim 57, wherein: The CNS cells are neuronal cells or microglial cells.
59. The method of any one of claims 53[000146]-58[000149], wherein the cargo remains functionally active within the CNS.
60. The method of any one of claims 53[000146]-59[000150], wherein the administration is intravenous or intraspinal.
61. A method of treating a CNS disorder or injury in a subject, comprising administering to a subject in need thereof one or more compositions of claims 24-31 or 46-52, wherein the cargo is a therapeutic agent for the CNS disorder or injury.
62. The method of claim 61, wherein the CNS disorder or injury is Parkinson's disease, Alzheimer's disease, glioblastoma, amyotrophic lateral sclerosis, multiple sclerosis, or traumatic brain injury.
63. The method of any one of claims 61G-62[000160], wherein the CNS disorder therapeutic agent is an antibody or a gene therapy.
64. A method of imaging the CNS of a subject, comprising administering to a subject in need thereof one or more compositions of claims 24-31 or 46-52, wherein the cargo is an imaging agent.
65. The method of any one of claims 61-64, wherein the composition enters the choroid plexus.
66. The method of any one of claims 61-65, wherein the composition enters the cerebrospinal fluid (CSF).
67. The method of claim 66, wherein the CSF transports the composition throughout the CNS.
68. The method of any one of claims 61-67, wherein the MGS targets the cargo to specific CNS cells.
69. The method of claim 68, wherein the CNS cell is a neuronal cell or a microglial cell.
70. The method of any one of claims 61-69, wherein the cargo remains functionally active within the CNS.
71. The method of any one of claims 61-70, wherein the administration is intravenous or intraspinal.
72. A linker comprising (i) at least one reactive group capable of binding to the C-terminus of a peptide; and (ii) at least one other reactive group capable of chemically reacting with a moiety.
73. The linker of claim 72, wherein the linker further comprises a lipid portion.
74. The linker of any one of claims 72-73, wherein the linker comprises two to four PEG linkers and a reactive group between at least two PEG linkers.
75. The linker of any one of claims 72-74, wherein the linker comprises an amino acid, a peptide, an alkyl, a maleimide, a thiol, a hydrazone, an amide.
76. The linker of claim 75, wherein the amino acid is a modified amino acid.
77. The linker of claim 76, wherein the modified amino acid is a functionalized lysine, a functionalized cysteine, a glutamic acid, an aspartic acid.
78. The connector of any one of claims 72-77, wherein the connector comprises the following structure: in, X is a peptide and R is a reactive group capable of chemically reacting with the moiety.
79. The connector of any one of claims 72-77, wherein the connector comprises the following structure: in, X is a peptide and R is a reactive group capable of chemically reacting with the moiety.
80. The connector of any one of claims 72-77, wherein the connector comprises the following structure: in, X is a peptide and R is a reactive group capable of chemically reacting with the moiety.
81. The connector of any one of claims 72-77, wherein the connector comprises the following structure: in, X is a peptide and R is a reactive group capable of chemically reacting with the moiety.
82. A linker as described in any of claims 72-81, wherein the reactive group is a carboxylic acid, an acyl halide, a sulfonyl halide, a chloroformates, an aldehyde, an alkyne, an alkyne (without an acetylenic hydrogen), an amide and an imide, an amine, a phosphine and a pyridine, an anhydride, azo, dinitrogen, azide, hydrazine and azide compounds, carbamates, epoxides, esters, sulfates, phosphates, thiophosphates and borates, halogenated organic compounds, isocyanates and isothiocyanates, ketones, oximes, sulfides (organic).
83. The linker of any one of claims 72-82, wherein the moiety is a cargo, and wherein the cargo is a dye, an imaging agent, a therapeutic agent, a protein, a nucleic acid, a peptide, or a lipid.
84. The linker of any one of claims 72-83, wherein the moiety is a linker.
85. A composition comprising: a. A peptide (MGS) comprising the amino acid sequence GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1), EQRWVQMLHLQTRYAGEWPG (SEQ ID NO: 2), or FQHNPYTYSMEDDVEIK (SEQ ID NO: 3); b. a first linker comprising (i) at least one reactive group capable of binding to the C-terminus of the peptide; and (ii) at least one other reactive group capable of chemically reacting with a moiety; c. The second joint; d. a third linker comprising (i) at least one reactive group capable of binding to the C-terminus of the peptide; and (ii) at least one other reactive group capable of chemically reacting with a moiety; and e. A peptide (MTS) comprising the amino acid sequence DAYKLQTSLDWQMWNP (SEQ ID NO: 9), FPSWTSKNQQWTNQRQ (SEQ ID NO: 11) or SKETYSMNAQRQHERS (SEQ ID NO: 13).
86. The composition of claim 85, wherein the first linker is attached to the C-terminus of a peptide (MGS) comprising the amino acid sequence GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1), EQRWVQMLHLQTRYAGEWPG (SEQ ID NO: 2), or FQHNPYPYTYSMEDDVEIK (SEQ ID NO: 3).
87. The composition of any one of claims 85-86, wherein the first linker is attached to the second linker.
88. The composition of any one of claims 85-87, wherein the second linker is attached to the third linker.
89. The composition of any one of claims 85-88, wherein the third linker is attached to the C-terminus of a peptide (MTS) comprising the amino acid sequence DAYKLQTSLDWQMWNP (SEQ ID NO: 9), FPSWTSKNQQWTNKRQ (SEQ ID NO: 11), or SKETYSMNAQRQHERS (SEQ ID NO: 13).
90. The composition of any one of claims 85-89, comprising: a. A peptide (MGS) comprising the amino acid sequence GFHNVYPYTWGGFSDIDLMADEI (SEQ ID NO: 1), EQRWVQMLHLQTRYAGEWPG (SEQ ID NO: 2), or FQHNPFPYTYSMEDTDVEIK (SEQ ID NO: 3); reactively attached to a first linker, wherein the first linker is attached to a second linker, wherein the second linker is attached to a third linker, wherein the third linker is attached to the C-terminus of a peptide (MTS) comprising the amino acid sequence DAYKLQTSLDWQMWNP (SEQ ID NO: 9), FPSWTSKNQQWTNQRQ (SEQ ID NO: 11), or SKETYSMNAQRQHERS (SEQ ID NO: 13).
91. A composition as described in any one of claims 85-90, wherein The composition comprises the following structure: Wherein X' is a peptide comprising the amino acid sequence DAYKLQTSLDWQMWNP (SEQ ID NO:9): FPSWTSKNQQWTNQRQ(SEQ ID NO:11): or SKETYSMNAQRQHERS(SEQ ID NO:13); and X is a peptide comprising the amino acid sequence DAYKLQTSLDWQMWNP (SEQ ID NO: 1): EQRWVQMLHLQTRYAGEWPG(SEQ ID NO:2): FQHNPFPYTYSMEDTDVEIK(SEQ ID NO:3); or YAAWPASGAWT (SEQ ID NO: 4): And R is a reactive group capable of chemically reacting with the moiety.
92. The composition of any one of claims 85-90, wherein The composition comprises the following structure: Wherein X' is a peptide comprising the amino acid sequence DAYKLQTSLDWQMWNP (SEQ ID NO:9): FPSWTSKNQQWTNQRQ(SEQ ID NO:11): or SKETYSMNAQRQHERS(SEQ ID NO:13); and X is a peptide comprising the amino acid sequence DAYKLQTSLDWQMWNP (SEQ ID NO: 1): EQRWVQMLHLQTRYAGEWPG(SEQ ID NO:2): FQHNPFPYTYSMEDTDVEIK(SEQ ID NO:3); or YAAWPASGAWT (SEQ ID NO: 4): And R is a reactive group capable of chemically reacting with the moiety.
93. A composition as described in any one of claims 85-90, wherein The composition comprises the following structure: Wherein X' is a peptide comprising the amino acid sequence DAYKLQTSLDWQMWNP (SEQ ID NO:9): FPSWTSKNQQWTNQRQ(SEQ ID NO:11): or SKETYSMNAQRQHERS(SEQ ID NO:13); and X is a peptide comprising the amino acid sequence DAYKLQTSLDWQMWNP (SEQ ID NO: 1): EQRWVQMLHLQTRYAGEWPG(SEQ ID NO:2): FQHNPFPYTYSMEDTDVEIK(SEQ ID NO:3); or YAAWPASGAWT (SEQ ID NO: 4): And R is a reactive group capable of chemically reacting with the moiety.
94. A composition as described in any of claims 85-93, wherein the MGS peptide has an N-terminal protecting group.
95. The composition of claim 94, wherein the N-terminal protecting group is an acetyl group.
96. The composition of any one of claims 85-93, wherein the MTS peptide has an N-terminal protecting group.
97. The peptide of claim 96, wherein the N-terminal protecting group is an acetyl group.
Citation Information
Cited By
Molecular transport system to central nervous system
CN115484970A
Molecular transport systems to the central nervous system
CN115484970B
